



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 16/28, A61K 39/395	A1	(11) International Publication Number: WO 98/37099 (43) International Publication Date: 27 August 1998 (27.08.98)
(21) International Application Number: PCT/US98/02253 (22) International Filing Date: 17 February 1998 (17.02.98) (30) Priority Data: 08/803,085 20 February 1997 (20.02.97) US Not furnished 5 February 1998 (05.02.98) US (71) Applicants: IDEC PHARMACEUTICALS CORPORATION [US/US]; 11011 Torreyana Road, San Diego, CA 92121 (US). SEIKAGAKU CORPORATION [JP/JP]; Tokyo Yakugyo Building, 2-1-5, Nihonbashi-honcho, Chuo-ku, Tokyo 103 (JP). (72) Inventors: REFF, Mitchell, E.; 4166 Combe Way, San Diego, CA 92122 (US). KLOETZER, William, S.; 4317 Sea Bright Drive, Carlsbad, CA 92008 (US). NAKAMURA, Takehiko; Tokyo Research Institute, 1253, Tateno 3-chome, Higashiyamato-shi, Tokyo 207 (JP). (74) Agents: GESS, E., Joseph et al.; Burns, Doane, Swecker & Mathis, L.L.P., P.O. Box 1404, Alexandria, VA 22313-1404 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: GAMMA-1 AND GAMMA-3 ANTI-HUMAN CD23 MONOCLONAL ANTIBODIES AND USE THEREOF AS THERAPEUTICS		
(57) Abstract Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FcεRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.		

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

**Gamma-1 and Gamma-3 Anti-Human CD23 Monoclonal
Antibodies and Use Thereof as Therapeutics**

Field of the Invention

The present invention relates to monoclonal
5 antibodies which specifically bind human CD23, the low
affinity receptor for IgE (FcεRII/CD23), and contain
either a human gamma-1 or human gamma-3 constant domain,
and their usage as therapeutic agents.

Background of the Invention

10 IgE is a member of the immunoglobulin family that
mediates allergic responses such as asthma, food aller-
gies, type 1 hypersensitivity and the familiar sinus
inflammation allergic rhinitis and conjunctivitis, and
as a result, causes widespread suffering throughout the
15 general population. IgE is secreted by, and expressed
on the surface of, B-cells. IgE synthesized by B-cells
can be anchored in the B-cell membrane by a short
transmembrane domain linked to the mature IgE sequence.
Membrane and secreted versions of IgE are formed in the
20 same cell by differential splicing of the IgE RNA
transcript.

IgE also can be bound to B-cells (and T cells,
monocytes, Langerhans cells, follicular dendritic cells,
natural killer cells, eosinophils and platelets) through
25 its Fc region to a low affinity IgE receptor (FcεRII,

-2-

hereafter "FCEL", and to mast cells and basophils through its Fc region to a high affinity IgE receptor FcεRI, (hereinafter "FCEH"). The low affinity IgE receptor is generally referred to in the literature as
5 CD23.

Upon exposure of a mammal to an allergen, antigen presenting cells process the antigen for presentation to helper T cells. These helper T cells secrete cytokines such as IL-4 which assist B-cells to undergo clonal
10 amplification and secrete more allergen-specific IgE. This newly synthesized IgE in turn is released into the circulation where it binds to mast cells and basophils through the high affinity receptor on their cell surface. Such mast cells and basophils are thereby
15 sensitized to the specific allergen. The next exposure to the same allergen causes binding to specific IgE on the surface of mast cells, and basophils, thereby cross-linking the FcεRI on these cells and thus activating their release of histamine and other factors
20 which are responsible for clinical hypersensitivity and anaphylaxis.

The art has reported antibodies capable of binding to FCEL (CD23)-bound IgE but not IgE bound to FCEH (see, for example, WO 89/00138 and U.S. Patent 4,940,782).
25 These antibodies are disclosed to be clinically advantageous because they bind to IgE which is bound to the low affinity receptor (FCEL) or to circulating IgE's, but do not bind to IgE bound to the high affinity receptor

-3-

(FCEH). Therefore, these antibodies will not activate mast cells or basophils.

Moreover, anti-CD23 antibodies have been reported to have potential as therapeutics, e.g., for the treatment of allergic disorders, inflammatory diseases, and autoimmune diseases. For example, Bonnefoy et al., WO 9612741, report that ligands which bind CD23, e.g., monoclonal antibodies, are useful in the treatment or prophylaxis of inflammatory, autoimmune and allergic diseases.

The usage of monoclonal antibodies to CD23, as both IgE agonists and antagonists has been reported. IgE antagonists have been reported to have potential utility in treatment of conditions or diseases wherein IgE suppression is therapeutically desirable, e.g., allergic conditions such as allergic rhinitis and conjunctivitis, atopic dermatitis and asthma. For example, Bonnefoy et al., WO 8707302 (1987), report monoclonal antibodies to human CD23, which are assertedly useful for assaying the presence of IgE receptors on cell types and as therapeutics in diseases wherein modulation of IgE is therapeutically desirable.

In part because of their potential as therapeutics and diagnostics, many groups have reported the generation of monoclonal antibodies to CD23. See, e.g., Rector et al., *Immunol.*, 55:481-488 (1985); Suemura et al., *J. Immunol.*, 137:1214-1220 (1986); Noro et al., *J. Immunol.*, 137:1258-1263 (1986); Bonnefoy et al., *J. Immunol.*, 138:2170-2178 (1987); Flores-Romo et al.,

-4-

Science, 261:1038-1046 (1993); Sherr et al.; *J. Immunol.*, 142:481-489 (1989); and Pene et al., *Proc. Natl. Acad. Sci., USA*, 85:6880-6884 (1988). Moreover, as discussed *supra*, the usage of such antibodies specifically to inhibit IgE production in systems where IgE synthesis is cytokine (IL-4) induced has also been reported. (Flores-Romo et al (*Id.*); Sherr et al. (*Id.*); Bonnefoy et al. (WO 8707302); Bonnefoy et al. (WO 8707302); Bonnefoy et al. (WO 9612741)); Bonnefoy et al., *Eur. J. Immunol* 20:139-144 (1990); Sarfati et al., *J. Immunol* 141:2195-2199 (1988) and Wakai et al., *Hybridoma* 12:25-43 (1993). Also, Flores-Romo et al. (*Id.*) disclose that Fabs prepared from anti-CD23 antibodies inhibit antigen-specific induced IgE responses *in vivo* in the rat. However, notwithstanding what has been reported, the mechanism by which anti-CD23 antibodies modulate IgE expression and in particular, the manner by which they block IL-4 induced IgE production remains unclear.

It has been suggested that anti-CD23 antibodies inhibit IgE production by signaling through CD23 present on the surface of IgE secreting B cells. It has been proposed that the function of CD23, which is upregulated on IgE secreting B cells, is feedback inhibition of IgE production (Yu, et al. *Nature* 369, 753-756 (1994)). This has been theorized because mice in which the CD23 gene has been removed have increased and sustained IgE production compared to controls (Yu, et al.). In addition, it has been reported that binding to CD23 by

-5-

IgE complexes or by a monoclonal antibody to anti-CD23 suppresses ongoing IgE synthesis by a lymphoblastoid cell line that constitutively secretes IgE (Sherr et al. (Id.)). It appears that this is due to down regulation of the messenger RNA for the secreted IgE heavy chain in this cell (Saxon et al., *J. Immunol.*, 147:4000-4006 (1991)). However, the exact mechanism by which IgE expression is inhibited has yet to be explained in systems in which IgE secretion is IL-4 induced.

It has also been reported that crosslinking of Fc gamma RII with surface Ig (B cell receptor) on B cells leads to down regulation of Ig expression. (D'Ambrosia et al., *Science*, 268:293-297 (1995)). A similar mechanism can be proposed for B cells secreting IgE which also have cell surface CD23 and Fc gamma RII. An anti-human CD23 antibody bound to a cell by antigen (CD23) and also bound to Fc gamma RII through Fc interactions could transmit a signal to suppress IgE secretion through Fc gamma RII.

Mechanisms involved in IgE inhibition by anti-CD23 antibodies have been proposed that include blocking interactions other than the interaction between membrane CD23 and IgE. Related to this, CD23, which is a member of the C-type lectin family, has been shown to interact with several other ligands such as CD21, CD11b and CD11c present on a variety of cell types including T cells and monocytes. In this context CD23 can be envisioned as a cellular adhesion molecule.

-6-

Therefore, it has been proposed that the CD21-CD23 interaction may be involved in antigen presentation and subsequent IgE production. Models suggest CD21 on B cells sending an activation signal for IgE production after binding to CD23 on activated T cells present primarily in atopic individuals. (Leconant et al., *Immunol.*, 88:35-39 (1996); and Bonnefoy et al., *Int. Amer. Allergy Immunol.*, 107:40-42 (1995).) Blocking this interaction with an anti-CD23 could block induced IgE production. (Aubry et al., *Nature*, 358:505-507 (1992) and *Immunol.*, 5:944-949 (1993); Grosjean et al. (1992); Bonnefoy et al., *Curr. Opin. Eur. J. Immunol.*, 24:2982-2988 (1994); Henchoz-Lecoanet et al., *Immunol.*, 88:35-39 (1996) Nambu et al., *Immunol. Lett.*, 44:163-167 (1995); Bonnefoy et al., *Int. Amer. Allergy Immunol.*, 107:40-42 (1995).) It is also possible that antigen presentation is upregulated by CD23 on antigen presenting B cells binding to CD21 on T cells.

Yet another mechanism which would potentially explain the effects of CD23 on IgE production involves soluble forms of CD23. It has been reported that CD23 is cleaved from the cell surface releasing several different forms of soluble CD23 or IgE binding factors. (Sarfati et al., *Immunol.*, 53:197-205 (1984).) Soluble CD23 is a cytokine, with one of its reported activities being the augmentation of IL-4 induced IgE production from B cells. (Pene et al., *J. Cell Biochem.*, 39:253-269 (1989); Pene et al., *Eur. J. Immunol.*, 18:929-935 (1988); Sarfati et al., *J. Immunol.*,

-7-

141:2195-2197 (1988); Sarfati et al. (1984) (*Id.*);
(Saxon et al., *J. Clin. Immunol. Allergy*, 86 (3 pt 1)
333-344 (1990). Also, certain forms of soluble CD23
have been reported to inhibit IgE production (Sarfati et
5 al., *Immunol.*, 76:662-667 (1992)). Accordingly,
anti-CD23 antibodies potentially may block IgE
production by 1) inhibiting the IgE augmenting effects
of soluble CD23 and/or 2) blocking the proteolytic
release of soluble CD23 from the cell surface.

10 Thus, based on the foregoing, it is clear that
there is significant complexity and uncertainty in the
art with respect to the functions of more specifically
CD23 and effects on IgE production, and further with
respect to the means by which ligands specific thereto
15 affect IgE production.

Objects of the Invention

Thus, it is an object of the invention to produce
novel ligands (antibodies) specific to CD23 and to use
such antibodies to elucidate the mechanism by which
20 anti-CD23 antibodies modulate IgE expression.

It is another object of the invention to produce
novel ligands (antibodies) which bind CD23, in
particular human CD23, having improved ability to
inhibit induced IgE expression.

25 It is a more specific object of the invention to
produce anti-human CD23 antibodies containing human
gamma-1 or human gamma-3 constant domains.

-8-

It is another object of the invention to produce multivalent anti-human CD23 antibodies which may be more effective by virtue of their enhanced potential for cross linking CD23 and Fc receptors.

5 It is another object of the invention to provide pharmaceutical compositions containing anti-human CD23 monoclonal antibodies comprising human gamma-1 or gamma-3 constant domains which are capable of inhibiting induced IgE production.

10 It is another object of the invention to use an anti-human CD23 monoclonal antibody comprising a human gamma-1 or human gamma-3 constant domain for treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable.

15 More specifically, it is an object of the invention to treat or prevent allergic conditions, autoimmune diseases and inflammatory diseases using an anti-human CD23 monoclonal antibody comprising either a human gamma-1 or human gamma-3 constant domain.

20

Brief Description of the Figures

Figure 1 compares the *in vitro* IgE inhibitory activity of a murine anti-human CD23 monoclonal antibody (MHM6), to five primate anti-human CD23 monoclonal antibodies (5E8, 6G5, 2C8, B3B11, and 3G12);

25

Figure 2 shows that primate monoclonal antibodies 5E8 and 6G5 bind an epitope on human CD23 that is distinct from commercially available murine anti-human CD23 monoclonal antibody MHM6 (middle panel, figure 2)

-9-

and compete with each other (lower panel, figure 2).
Primate anti-human CD23 monoclonal antibodies 2C8 and,
B3B11 compete with MHM6 top panel, figure 2).

Figure 3 compares the *in vitro* IgE inhibitory
5 activity of a particular primate anti-human CD23
monoclonal antibody 5E8 to four different PRIMATIZED®
versions of said primate monoclonal antibody, the
sequences of which are described below.

- 10 p5E8G4P- This PRIMATIZED® antibody contains the
following sequences:
Human kappa light chain constant region
and a human gamma 4 constant region which
contains a P mutation (Angal et al., *Mol.*
Immunol., 30:105-108 (1993));
- 15 p5E8G4PN- This PRIMATIZED® antibody contains the
human kappa light chain constant region
and a human gamma 4 constant region
having a P mutation (Angal et al. *Mol.*
Immunol., 30:105-108 (1993)). This
20 antibody also contains a mutation in the
heavy chain variable region which changes
an asparagine residue (potential
carbohydrate attachment site) to a
lysine;
- 25 p5E8G1 This PRIMATIZED® antibody contains the
human kappa light chain constant region
and a human gamma 1 constant region;
- p5E8G1N- This PRIMATIZED® antibody contains the
human kappa light chain constant region

-10-

and human gamma 1 constant region. This antibody also contains a mutation in the heavy chain variable region which changes an asparagine residue (carbohydrate attachment site) to a lysine;

Figure 4 contains a table which compares the apparent Kd in nM of the antibodies identified in Figure 3 and summarizes their IgE suppressive activity.

Figure 5 compares the *in vitro* IgE inhibitory activity of a particular primate anti-human CD23 monoclonal antibody, 6G5, to two different PRIMATIZED® versions of 6G5 which are described below:

p6G5G1 This PRIMATIZED® antibody contains the human lambda light chain constant region and the human gamma 1 constant region;

p6G5G4P This PRIMATIZED® antibody contains the human lambda light chain constant region and the human gamma 4 constant region with a P mutation (Angal et al., *Mol. Immunol.*, 30:105-108 (1993));

Figure 6 compares the *in vitro* IgE inhibitory activity of primate anti-human CD23 monoclonal antibody 2C8 to F(ab')₂ derived from 2C8;

Figure 7 shows that the F(ab')₂ derived from 2C8 antagonizes the suppression of *in vitro* IgE activity of primate anti-human CD23 monoclonal antibody 2C8.

Figure 8 shows the *in vivo* IgE inhibitory activity of a particular primate anti-human CD23 monoclonal antibody, 5E8, in a SCID animal model;

-11-

Figure 9 compares the *in vivo* inhibitory activity of primate anti-human 6G5 and a PRIMATIZED® version thereof p6GSG4P.

5 Figure 10 shows the *in vivo* IgE inhibitory activity of the primate anti-human CD23 monoclonal antibody 6G5 and a PRIMATIZED® version thereof, p6G5G1.

Definition of Terms Used in This Application

Chimeric Antibody:

10 A recombinant antibody containing regions from two different antibodies, usually different species antibodies, most typically rodent variable sequences and human constant domain sequences.

Anti-Human CD23 Gamma 1 Antibody

15 An antibody that specifically binds human CD23 which contains a human gamma 1 constant region or fragment or modification thereof which inhibits induced IgE production. This includes, in particular, antibodies containing rodent or primate variable domains or antigen binding portions, humanized, PRIMATIZED®, and
20 human anti-human CD23 monoclonal antibodies which comprise a human gamma 1 constant domain, fragment, or modification thereof, which inhibit induced IgE production *in vitro*.

Anti-Human CD23 Gamma 3 Antibody

-12-

An antibody that specifically binds human CD23 which contains a human gamma 3 constant region or fragment or modification thereof which inhibits induced IgE production. This includes, in particular, antibodies containing rodent or primate variable domains or antigen binding portions, humanized, PRIMATIZED®, and human anti-human CD23 monoclonal antibodies which comprise a human gamma 3 constant domain, fragment, or modification thereof, which inhibit induced IgE production *in vitro*.

Modifications of Antibody Constant Domains

Antibodies according to the present invention containing mutations, substitutions or deletions of the constant region, that may create a desired change in the level of efficiency, i.e. in FcR binding, without changing the basic effector functions mediated by the constant region.

PRIMATIZED® Antibody

A recombinant antibody containing primate variable sequences or antigen binding portions, and human constant domain sequences.

Humanized Antibody:

A recombinant antibody containing a non-human variable region or antigen binding portion which has been modified to more closely mimic a human antibody variable region and thereby eliminate or minimize potential

-13-

immunogenicity if administered to humans without sacrificing the specificity or affinity of the immunoglobulin. There are several known methods of humanization, including, "veneering" which comprises
5 select modification of surface residues, framework replacement, (CDR grafting) and molecular modeling.

Gamma 1 Constant Domain:

A particular type of constant domain sequence which confers upon an antibody specific effector activities.
10 In the present application, gamma 1 constant domain refers to a human gamma 1 constant domain, fragment or modification thereof, which retains gamma 1 effector functions in combination with anti-CD23 variable domain sequences or antigen binding portions. Modifications
15 include human gamma-1 constant domains which comprise the deletion, substitution or addition of one or more amino acid residues. This effector function is manifested by the ability of an antibody containing such a constant domain to inhibit induced IgE production.

20 Gamma 3 Constant Domain:

A particular type of constant domain sequence which confers upon an antibody specific effector activities. In the present application, gamma 3 constant domain refers to a human gamma 3 constant domain, fragment or
25 modification thereof, which retains gamma 3 effector functions in combination with anti-CD23 variable domain sequences or antigen binding portions. Modifications

-14-

include human gamma-3 constant domains which comprise the deletion, substitution or addition of one or more amino acid residues. This effector function is manifested by the ability of an antibody containing such a constant domain to inhibit induced IgE production.

CD23:

This refers to the low affinity receptor for IgE, FcεRII/CD23.

Anti-CD23 Antibody:

10 An antibody that specifically binds CD23, preferably human CD23.

Detailed Description of the Invention

As discussed *supra*, while many groups have previously reported the production of anti-CD23 antibodies and the use thereof as antagonists and agonists for modulating IgE production, the exact mechanism by which such antibodies modulate IgE expression in systems where IL-4 induces IgE production remains unclear. Thus, it would be beneficial if the means by which such antibodies modulate IgE expression were elucidated, or at least better explained, as such information would be potentially useful in designing therapeutics for treatment of diseases wherein modulation of IgE production is therapeutically desirable. In particular, it would be beneficial if improved antibodies specific to CD23 were obtained

-15-

having improved capacity to inhibit induced IgE production, as enhanced IgE levels are believed to be involved in numerous disease processes, e.g., allergic conditions, inflammatory conditions and autoimmune diseases. Such diseases include by way of example, atopic dermatitis, eczema, allergic rhinitis and conjunctivitis, Job's syndrome, and asthma.

Toward that end, the present inventors have surprisingly discovered that anti-human CD23 monoclonal antibodies which contain human gamma-1 constant domains inhibit IgE production in systems where IgE production is induced by IL-4 significantly better than CD23 monoclonal antibodies of other effector types, e.g., those comprising human gamma-4 constant domains or CD23 monoclonal antibodies or antibody fragments lacking effector functions altogether. Because human gamma-3 constant domains have been shown to mediate the same effector functions as human gamma-1, anti-human CD23 monoclonal antibodies containing human gamma-3 constant domains are also included.

There are currently five defined effector functions for the IgG (gamma) class of antibodies. Two of these functions, complement activation and FcγRN interaction, are not found in the in vitro assays described in the present invention, and are therefore not likely to be involved in the molecular mechanism. Three other FcγR receptors have been identified which interact with the IgG class of antibodies: FcγRI, FcγRII (of which there are at least six different proteins) and FcγRIII (with

-16-

at least two different proteins). All three of these receptors interact with both IgG1 and IgG3.

FcγRI is the only one of the three having an appreciable affinity for IgG. It binds both monomeric
5 gamma-1 and gamma-3 with a K_a of about $5 \times 10^8 \text{ M}^{-1}$. However, its affinity for human gamma-4 is about 10-fold less, and it does not bind human gamma-2 at all (Fries et al., 1982, J. Immunol. 129: 1041-1049; Kurlander and Batker, 1982, J. Clin. Invest. 69: 1-8; Woof, 1986, G.
10 Mol. Immunol. 21: 523-527; see also Burton and Woof, 1992, Human Antibody Effector Function, Adv. Immunol. 51: 1-84).

Although the affinity of human FcγRII and FcγRIII for human IgG is generally very low ($K_a < 10^7 \text{ M}^{-1}$), affinity
15 for human IgG1 and human IgG3 increases significantly ($K_a \approx 2$ to $5 \times 10^7 \text{ M}^{-1}$) when they are bound to antigen (Karas et al., 1982, Blood 60: 1277-1282). The affinity of human FcγRII for human IgG2 bound to antigen has
20 given conflicting results. Human FcγRIII does not bind to human IgG2. Human FcγRII and human FcγRIII do not bind to human IgG4 (Van de Winkel and Anderson, 1991, J. Leuk. Biol. 49: 511-524; Huizinga et al., 1989, J. Immunol. 142: 2359-2364).

While Fc mediated effector functions are sometimes
25 significant to the therapeutic activity of antibodies, this discovery was surprising in the case of anti-CD23 antibodies because the role of effector function in the IgE inhibitory activity of anti-CD23 antibodies had not been previously reported. In fact, previous evidence

-17-

had suggested that antibody effector function was not significant to the ability of anti-CD23 antibodies to inhibit induced IgE production. For example, Flores-Romo et al., *Science*, 261:1038-1041 (1993) had reported that Fabs prepared from a polyclonal anti-CD23 antibody inhibited an *in vivo* induced IgE antigen-specific response.

The discovery that effector functions mediated through the constant region of the anti-CD23 antibodies are apparently involved was made after the present inventors isolated various primate antibodies specific to CD23 having anti-IgE inhibiting activity and compared these antibodies to PRIMATIZED® versions with respect to their ability to inhibit IL-4 induced IgE production *in vitro* and *in vivo*. Antibodies constructed with a human gamma-4 constant region failed to inhibit IgE antigen-specific responses *in vitro*, whereas antibodies containing a human gamma-1 constant region were successful.

Because one (or more) of the three classes of FcγR receptors, FcγRI, FcγRII or FcγRIII, is likely involved in the specific effector function mediated through the gamma-1 domain, and because these classes of receptors also bind to antibodies containing gamma-3 domains, it is logical that anti-CD23 antibodies containing gamma-3 domains will also be successful at inhibiting IgE-antigen specific-response *in vitro*.

More specifically, and as described in greater detail *infra*, five primate monoclonal antibodies which

-18-

specifically bound both cellular and soluble CD23 were isolated from an Old World monkey (macaque) according to the methodology which is disclosed in commonly assigned Application Serial No. 08/379,072 (now allowed), which application is incorporated by reference in its entirety herein. This application described in detail a means for producing monoclonal antibodies to desired antigens, desirable human antigens, in Old World monkeys and their advantages in relation to antibodies of other species as therapeutics, for example reduced or potentially lack of immunogenicity in humans because of the phylogenetic closeness of humans and Old World monkeys. In fact, because of the phylogenetic closeness of these species, it is difficult to distinguish Old World monkey immunoglobulins from human immunoglobulins by sequence comparison.

Four of these five primate monoclonal anti-human CD23 antibodies were demonstrated to be capable of inhibiting IL-4 induced IgE production in an *in vitro* B cell assay described in detail *infra* and the most potent was also shown to inhibit IL-4 induced IgE in a SCID mouse animal model (also described in detail *infra*). Based on this IgE inhibitory activity, and expected low immunogenicity in humans, such antibodies are potentially suitable as therapeutics for treating diseases wherein inhibition of IgE production is therapeutically desirable.

However, in order to further reduce immunogenicity, it was elected to PRIMATIZE® two primate monoclonal

-19-

antibodies (a type of chimerization of antibodies) according to the methodology which is also described in U.S. Serial No. 08/379,072 (now allowed), incorporated by reference herein. PRIMATIZATION® essentially refers to the production of recombinant antibodies developed by IDEC Pharmaceuticals Corporation which comprise primate variable regions and human constant regions. Primatization of the two primate anti-human CD23 monoclonal (5E8 and 6G5) antibodies having potent IgE inhibiting activity was effected in order to eliminate any potential immunogenicity attributable to the primate constant domains in humans.

Again, because of the inventors' initial expectation from published literature that Fc effector function was not necessary for induced IgE inhibition, human gamma 4 versions of these particular antibodies were initially produced. However, quite surprisingly, it was found that the gamma-4 versions produced from both of these primate monoclonal antibodies were ineffective, i.e., they required significantly higher concentrations of PRIMATIZED® gamma 4 antibody than the primate antibody to inhibit IL-4 induced IgE production in in vitro assays.

Moreover, even more surprising was the discovery that when the same two primate antibodies were then converted to human gamma-1 versions (by substitution of the primate constant domains with human gamma-1 constant domains), that these gamma-1 antibodies very effectively inhibited induced IgE production in vitro. Thus, our

-20-

results suggested that Fc effector function is apparently significant to the ability of anti-human CD23 antibodies to inhibit induced IgE production. This hypothesis was confirmed when a third primate anti-human CD23 monoclonal, i.e., the 2C8 antibody, which was shown by us to inhibit IgE production *in vitro*, was converted to a F(ab')₂, which was found to be substantially incapable of inhibiting induced IgE production *in vitro*. In fact, this F(ab')₂ was found to antagonize the suppressive effects on induced IgE blocking activity of the primate anti-human CD23 monoclonal antibody 2C8.

In addition, it was found that removing a glycosylation site in the heavy chain variable region of one of the antibodies (5E8) had no effect on binding of the antibody to CD23 (as evidenced by obtained K_d values), or on induced IgE inhibition. Thus, the differences in IgE inhibition were shown to apparently not involve glycosylation differences.

The PRIMATIZED® gamma 1 version of primate 6G5 was found to inhibit induced IgE expression in SCID mice while the same concentration of either the primate 6G5 or the PRIMATIZED® p6G5F4p did not inhibit induced IgE expression. Therefore, an antibody containing human gamma-1 constant domains was found to be even more effective in an *in vivo* animal model than the primate monoclonal antibody. Furthermore, the inventors anticipate that anti-CD23 antibodies containing human gamma-3 constant domains will be just as effective as those having gamma-1 constant domains, because gamma-1

-21-

and gamma-3 constant domains have affinity for the same classes of Fc receptors.

Accordingly, based on these results, it has been surprisingly discovered that an active Fc region, in particular that of human gamma-1 or human gamma-3, is significantly involved in the mechanism of IL-4 induced IgE inhibition by anti-human CD23 monoclonal antibodies. This discovery is quite unexpected especially based on earlier reports that Fabs derived from polyclonal anti-CD23 antibodies were capable of inhibiting induced IgE production, and also based on the various theories as to how CD23 affects induced IgE expression.

Accordingly, the present invention relates to anti-human CD23 antibodies containing human gamma-1 or gamma-3 constant domains and their use as therapeutics based on their ability to effectively inhibit IgE expression.

The skilled artisan can prepare anti-human CD23 antibodies containing either human gamma-1 or gamma-3 constant domains by methods which are well known in the art for the manufacture of chimeric antibodies. Essentially, such methods comprise producing anti-human CD23 antibodies in a desired host or *in vitro*, cloning a hybridoma or cell line which produces an anti-human CD23 monoclonal antibody exhibiting desirable characteristics, e.g., adequate CD23 binding affinity, cloning the nucleic acid sequences which encode such antibody from said hybridoma or cell line, e.g. by polymerase chain reaction using suitable primers, isolating the

-22-

variable domains contained therein, recombining such variable domains with human gamma-1 or gamma-3 constant domains and the appropriate human light chain constant domain, and expressing the resultant nucleic acid sequence encoding a chimeric anti-human CD23 gamma-1 or gamma-3 immunoglobulin in a suitable expression system. Preferably, the anti-human CD23 antibodies of the invention will have apparent CD23 binding affinities ranging from 0.1 nM to 1000 nM, more preferably at least 50 nM, and most preferably at least 5 nM.

Host cells suitable for expression of recombinant immunoglobulins are well known in the art. For example, recombinant antibodies may be expressed in Chinese hamster ovary (CHO) cells, DG44 or DUXB11; or CHO cells CHO K-1; mouse myeloma cells SP2/0 or X63-Ag8.653 or NSO; rat myeloma cells YB2/0; baby hamster kidney cells, BHK; human embryonic kidney line, 293; monkey kidney cells, CV1; human lung fibroblasts, WI38; human cervical carcinoma cells, HELA; insect cells, plant cells, yeast or in bacteria. Further, vectors suitable for expression of immunoglobulins are also well known in the art and are commercially available.

A particularly preferred vector system is the translationally impaired vector system disclosed in U.S. Serial No. 08/147,696 (now allowed), which comprises a translationally impaired dominant selectable marker (neo) containing an intron into which a desired heterologous DNA is inserted. This vector system has been found to provide for very high yields of

-23-

recombinant proteins, e.g., immunoglobulins. However, the subject anti-CD23 antibodies may be produced in any vector system which is suitable for expression of functional immunoglobulins.

5 Also, the present invention embraces human monoclonal antibodies of the gamma-1 or gamma-3 types which are specific to human CD23. Methods for isolation of human monoclonal antibodies are also well known in the art and include *in vitro* methods, e.g., *in vitro*
10 immunization of human B cells in tissue culture, and *in vivo* methods, e.g. synthesis of human monoclonal antibodies in SCID mice. A preferred means of producing human monoclonal antibodies in SCID mice which combines *in vitro* priming of human spleen cells which are then
15 introduced into SCID mice is disclosed in U.S. Serial No. 08/488,376 (incorporated by reference in its entirety herein). This method is advantageous as it provides for the reproducible recovery of monoclonal antibodies having high affinity against a desired anti-
20 gen, e.g., a human antigen.

Also, the present invention embraces human monoclonal antibodies which compete with the primate anti-human CD23 monoclonal antibodies 5E8 and 6G5 for binding to CD23.

25

EXAMPLE 1

Production of Primate Anti-CD23 Antibodies

Five primate monoclonal antibodies specific to CD23 were isolated from macaques substantially according to

-24-

the methodology disclosed in Serial No. 08/379,072, which has been incorporated by reference herein. The exact techniques utilized are described in detail below.

Methodology for Isolation and Characterization
of Anti-Human CD23 Monoclonal Antibodies

Purification of the Immunogen sCD23 from 8866 cells

During purification, soluble CD23 (sCD23) was quantified by a three-step ELISA using a murine anti-CD23 antibody (Binding Site; catalog # MC112) as a capture. The antigen was partially purified from cultures of 8866 cells maintained in suspension bioreactors using RPMI 1640 (JRH Biosciences; catalog # 56-509) supplemented with 10% fetal bovine serum (JRH Biosciences) and 4 mM glutamine (JRH Biosciences; catalog # 90114) at 37°C. Carbon dioxide was used to maintain pH 7.1. After removing cells by 0.45 μ m filtration, phenylmethyl sulfonyl fluoride (final concentration 0.2 mM, Sigman Chemical Co.; catalog # P-7626) and ethylenediaminetetraacetic acid (final concentration 3 mM, Sigma Chemical Co.; catalog # EDS) were added to the supernate and the solution stored at 2-8°C. The cell-free supernate was concentrated approximately 15 to 20-fold using a hollow-fiber ultrafiltration cartridge (A/T Technology; catalog # UFP-10-C-9A; 10,000 d MWCO) or tangential flow ultrafiltration cartridge (Filtron Corporation; 10,000 d MWCO) at ambient temperature. The concentrated supernate was sterile filtered and stored at -70°C.

-25-

Thawed concentrates were de-lipidated by adding SM-2 BioBeads (BioRad Industries; catalog # 152-3920) at 5 g/L and stirring overnight at 2-8°C. The resin was removed by filtration and the solution stored at 2-8°C.

- 5 For some preparations of sCD23, concentrates were fractionated using ammonium sulfate (35-70% (w/v); Fisher; catalog # A702-3) before or after de-lipidation.

- The de-lipidated solution was subsequently purified using affinity chromatography at 2-8°C. The affinity
10 matrix was prepared by covalently linking a murine anti-CD23 monoclonal antibody (BU38) to Sepharose using CNBr-activated Sepharose 4B (Sigma Chemical Co.; catalog # C-9142). The BU38 antibody was purified to >90% homogeneity from ascites (Binding Site; catalog #
15 CUS830) using Protein A chromatography. The de-lipidated solution was applied to the affinity column (1.5 x 5 cm) equilibrated with 1XPBS (Gibco BRL; catalog # 70013-0.32), pH 7.2 and the column washed with 1XPBS, pH 7.2, containing 0.05% NP40 (Sigma Chemical Co.) to
20 remove non-bound protein. Soluble CD23 was eluted using 3.5 M MgCl₂ (Fisher; catalog # M33-500). Fractions containing sCD23 were combined and dialyzed (Baxter Spectra/Por; catalog # D1615-1) against 1XPBS, pH 7.2 at 2-8°C. After dialysis, the protein solution was
25 concentrated by centrifugation using Centriprep 10 spin filters (Amicon Corporation; MWCO 10,000 d) and preparations stored at -70°C. The purity of sCD23 was estimated to be >70% using SDS-PAGE analysis (4-20% pre-cast gels, Novex Corporation) and Coomassie staining.

-26-

Immunization of Primates and Isolation of Immune Cells

Cynomolgus monkeys (White Sands Research Center, Alamogordo, New Mexico) were immunized with soluble CD23 which had been purified from the supernatant of human
5 RPMI 8866 cells (B cell lymphoma, Hassner and Saxon, *J. Immunol.*, 132:2844 (1984)). Each monkey was immunized every third week with 200 μ g soluble CD23 in 500 μ l PBS mixed with 167 μ l Temuritide (adjuvant peptide) (Sigma, St. Louis, MO, Catalog # A-9519) and 333 μ l 3X PROVAX®
10 (IDEC Pharmaceuticals Corporation). Immunization was effected intradermally, intraperitoneally, intramuscularly and subcutaneously. The titer of anti-CD23 antibodies in the serum of the monkeys was measured by ELISA on 8866 cells and compared to a
15 pre-bleed from the same monkeys.

Monkey PRO 978, with a serum titer of fifty thousand was sacrificed, and the spleen and lymph nodes were surgically removed, and shipped on ice to IDEC pharmaceuticals, submerged in sterile RPMI-1640 (Gibco
20 BRL, Gaithersburg, MD, Catalog # 21870-050) supplemented with 10% fetal calf serum, 2 mM L-glutamine, 2 mM sodium pyruvate and 50 μ g/ml gentamicin. Immediately upon arrival the spleen was homogenized by squeezing it through a wire mesh with a glass pistil. Red blood
25 cells were lysed in an ammonium chloride based hypotonic buffer and the remaining lymphocytes collected and washed in RPMI-1640 at least three times. Lymph nodes were homogenized similarly into a single cell

-27-

suspension, collected and washed at least three times in RPMI-1640.

Production of Hybridomas

After the last wash, the cells were counted, and
5 the primate cells obtained above were then somatically
fused to the mouse-human heterohybridoma cell line
H6K6/B5 (Carroll et al., *J. Immunol. Methods*, 89:61
(1986)) using standard techniques (Boerner et al., *J.*
Immunol., 147:86) (1991)) and plated into 96 well dishes
10 (175 dishes or 14,700 wells for the spleen, and 17
dishes or 1386 wells for the lymph nodes) at 300,000
cells per well.

This procedure involved the mixing of lymphocytes
and the above-identified fusion partner, at a 2:1 ratio,
15 which cells were slowly resuspended into 50% PEG 1500
(Sigma, Catalog # P5402) for 1 minute. These cells were
then allowed to rest for 1 minute and then slowly
further resuspended in excess RPMI-1640. Afterward, the
cells were again allowed to rest, this time for 15
20 minutes before a light spin at 250 x g. The cells were
then resuspended in RPMI-1640 growth media, which was
supplemented with 20% Fetal Calf Serum, 2 mM
L-Glutamine, Sodium Pyruvate, Non-Essential Amino Acids
and 50 µg/ml Gentamicin, containing 100 µM Hypoxanthine,
25 16 µM Thymidine (BoehringerMannheim, Germany, # 623091)
and 5.8 µM Azaserine (Sigma, Catalog # A 1164) (HTA).
HTA is a selection agent which provides the survival of

-28-

successfully fused cells (primate lymphocyte fused with heterohybridoma fusion partner).

Approximately 65% of the wells showed growth (10,500 wells). These wells were then screened for the presence of anti-human CD23 antibody by a three step cell ELISA.

ELISA Procedure

The first step of the ELISA comprised the transferral of fifty microliters of supernatant from each well to ninety-six well plates which had previously been coated with 10^5 8866 cells (CD23 positive cell line) per well. These plates were made by first coating the plates with 50 μ l of aqueous solution containing twenty μ g/ml Poly L-Lysine (Sigma Catalog # P1399, MW 150,000 - 300,000) for thirty minutes at room temperature. The remaining solution was removed ("flicked out") and the plates left to dry. Once dry, fifty μ l of 8866 cells in PBS were transferred and spun at 600 g for five minutes. The 8866 cells were covalently bound to the plate by adding fifty μ l 0.5% glutaraldehyde (Sigma Catalog # G6257) in phosphate buffered saline (PBS) for 15 minutes. The glutaraldehyde was removed (flicked out) and the plates blocked with one hundred fifty μ l 100 mM glycine (Sigma Catalog # G-2879) in 0.1% BSA - PBS. After the addition of supernatants, the plates were incubated at 37°C for one to two hours and washed seven to nine times with tap water, and a goat anti-human IgG antibody coupled to horse radish peroxidase (HRPO)

-29-

(Southern Biotech, Birmingham, Alabama, Catalog # 2040-05) diluted 1:2000 into 1% dry skimmed milk (Vons) in PBS - 0.05% Tween 20 (Sigma, Catalog # P1379) was added. The plates were incubated for forty-five minutes at 37°C, and again washed seven to nine times in tap water. The presence of the HRPO was detected by a color development after the addition of a TMB reagent (Kirkegaard & Perry, Gaithersburg, MD, Catalog # 50-76-02 and 50-65-02), 100 µl/well. The reaction was stopped by adding twenty-five µl 4N H₂SO₄. Optical density (OD) was measured at 470 nm on a spectrophotometer (Titertek Multiscan). The OD values greater than two times the background were scored as positive.

The second step in the ELISA was effected to confirm that the supernatants which had been scored positive in the first ELISA reacted to CD23 and not to some irrelevant antigen. This was effected by testing the supernatants on SupT1 cells (ERC BioServices Corporation, Rockville, MD, Catalog # 100), a CD23 negative human cell line, using the same ELISA procedure. Supernatants that scored similarly in both tests were discarded. These results indicated that fifty-six of the 10,500 wells with growth showed the presence of a primate monoclonal antibody that bound to 8866 cells in two separate screenings at different times and did not bind to SupT1 cells.

The third step of the ELISA was conducted to determine whether the supernatants identified according to

-30-

the first two ELISA steps, reacted with soluble CD23. In this third ELISA, 96 well plates were coated at 4°C overnight with 2 µg/ml BG-6 (Biosource International, Camarillo, CA, Catalog # CT-CD23-CF), a mouse monoclonal antibody that binds to soluble CD23 but does not block CD23-IgE binding, contained in a 50 mM bicarbonate buffer, pH 9.3. After removing the coating buffer, fifty µl of semi-purified soluble CD23 at a predetermined dilution in PBS were added to the plate and incubated for two hours at room temperature. After washing the plate with tap water seven to nine times, 50 µl supernatants from selected wells were added. After washing the plate in tap water seven to nine times, 50 µl rabbit anti-human IgG (mouse adsorbed)-HRPO (Southern Biotech, Catalog # 6145-05) diluted 1:4000 in 1% dry skimmed milk in PBS with 0.05% Tween 20 were added, incubated for two hours at 37°C, washed seven to nine times in tap water and developed with TMB as described above. Wells with OD's greater than two times the background were again scored as positive.

Twenty-one of the fifty-six wells that showed binding to 8866 cells also bound to sCD23 in the ELISA. These wells were expanded and subcloned at least twice by plating out cells at one cell per three wells. After approximately three months, five stable hybridomas producing primate monoclonal antibodies to CD23 were obtained.

-31-

Antibody Purification by Protein A Methods

Essentially, antibodies are purified by centrifugation of the culture supernatant to remove cells and debris. The resultant centrifuged samples are then
5 filtered through a 0.2 μ m filter. A protein A sepharose Fast flow column is then prepared and equilibrated using PBS (pH 7.4). The supernatant is then loaded on the column at an appropriate flow rate (2 ml/min). After loading, the wash column is washed with 10 column volume
10 of PBS (pH 7.4). The antibody is then eluted from the column with elution buffer (0.2 M acetic acid, 0.1 M glycine pH 3.5) at 1 ml/min flow rate. One milliliter fractions/tube (2.0 M Tris-HCl pH 10.0) including 100 μ l of Tris, are then collected. Afterward,
15 spectrophotometer readings are taken at 280 nm. The resultant fractions with high absorbance at 280 nm containing the antibody are then collected and dialyzed against PBS overnight. The product is then sterilized by filtration through 0.22 μ m membrane and stored at -
20 20°C.

Four of these five primate anti-human CD23 monoclonal antibodies (1H6, 2C8, 5E8 and 6G5) were demonstrated to inhibit IgE production in an *in vitro* assay which measures IgE production by
25 IL4-hydrocortisone induced peripheral blood mononuclear cell (PBMC) cultures. These results are shown in Figure 1. The assay conditions are described below. The fifth primate monoclonal anti-human CD23 antibody B3B11 was inactive in this assay.

-32-

IL-4 Stimulated IgE Production
by Peripheral Blood Mononuclear Cells

As discussed supra, the subject primate antibodies and PRIMATIZED® forms thereof were assessed for their
5 ability to inhibit IgE production in an *in vitro* assay which measured the effect of such antibodies on IgE production by IL-4 stimulated peripheral blood mononuclear cells.

Materials for in vitro IL-4 IgE Assay

10 Forty-eight well flat bottom cluster plates (Costar Catalog # 3548) (1.5 million PBMCs per ml per well (48 well plate))

Human recombinant IL-4 (Genzyme Catalog # 2181-01;
10 µg (2.5 x 10⁷ units).

15 anti-CD23 Mabs:

murine Mab (MHM6; DAKO. Catalog # M763)

primate Mabs (no preservatives)

PRIMATIZED® (no preservatives)

20 HB 101 basal medium: (Irvine Scientific Catalog # T000)

HB101 supplement: (Irvine Scientific Catalog # T151)

Fetal Bovine Serum: (FBS; Bio-Whittaker Catalog # 14-501F)

25 dimethylsulfoxide: (DMSO; Fisher Scientific Catalog # D128-500)

hydrocortisone: (Sigma Catalog # H-0888)

puromycin: (Sigma Catalog # P-7255)

-33-

cyclohexamide: (Sigma Catalog # C-7698)

Histopaque®: (Sigma Catalog # H-8889)

Hank's Buffered Salt Solution: (HBSS; Irvine Scientific Catalog # 9232)

5 1% FBS in HBSS

concentrated Dulbecco's phosphate buffered saline
(10x DPBS; Bio-Whittaker, Catalog # 17-517Q)

Bath Clear Microbicide (Fisher, Catalog #
13-641-334) in DPBS

10 Solutions:

puromycin solution: 40 µg/ml in HB101 growth
medium

cyclohexamide solution: 200 µg/ml in HB101 growth
medium

15 hydrocortisone solution: 0.1 M solution in DMSO
anti-CD23 murine Mabs were extensively dialyzed to
remove preservatives

HB101 growth medium

HB101 basal medium 500 ml

20 HB101 supplement in 10 ml

sterile filtered distilled H₂O 5 ml

FBS 10 ml

hydrocortisone solution

(final conc. 5 µM) 0.25 ml

25

In Vitro Assay Procedure

Buffy coat cells 1:4 are diluted using HBSS at room
temperature. These cells are derived from whole blood

-34-

after an overnight incubation at room temperature to resolve and separate the plasma components, clotted platelets and fibrin, and buffy coat cells.

Thirty microliters of diluted buffy coat are then
5 overlaid onto fifteen microliters of Histopaque in
fifty ml conical tubes. These tubes are then
centrifuged for twenty minutes at 1700 rpm at room
temperature without brakes (IEC 216 swinging bucket
rotor). The white PBMC layer is then collected using a
10 sterile pipette, taking care not to disturb the other
layers. The PBMCs (peripheral blood mononuclear cells)
are the buffy coat cells which have been sedimented by
centrifugation partially through a HISTOPAQUE® density
gradient to form a distinctly visible white layer of
15 cells. These cells are collected with a pipette, rinsed
with HBSS, and then counted using a hemocytometer.
Typically, 300 to 600 million PBMCs can be recovered
from a single 450 ml buffy coat package.

The collected PBMCs are then washed three times in
20 1% FBS/HBSS. The washed cells are collected by centrifuga-
tion for seven minutes at 1300 rpm at 7°C.

The number of cells collected is then determined
using a hemocytometer. The cell concentration is
adjusted to about three million cells per milliliter of
25 HB101 growth medium.

Approximately about 1.5 million cells (0.5 ml) are
then added to each well of a 48 well plate. In general,
five replicate samples are prepared for each experiment.
The perimeter wells of each plate are not used for cell

-35-

samples. Accordingly, these wells are filled, e.g., using 0.5 ml of 0.05% BathClear/DPBS.

0.5 ml HB101 growth medium containing desired amounts of IL-4 and Mab is then added to the wells. The
5 IL-4 used is recombinant DNA-generated human interleukin 4. The Mab used in the assay is a murine, primate or PRIMATIZED® antibody. Typically, IL-4 is added at a final concentrate of 100 U/ml and Mab is added at a final concentrate ranging from 0.01 to 3 µg/ml.

10 The cells are then incubated for nine to eleven days at 37°C in a moist incubator set at 5% CO₂. After incubation, the supernatant fluids are collected and the IgE content is measured.

IgE ELISA

15 The following list identifies materials and solutions used in the IgE ELISAs.

Materials and Solutions Needed for IgE ELISA

sulfuric acid, 4 M

coating buffer: 10 mM sodium bicarbonate buffer, pH 9.6

20 concentrated phosphate buffered saline (10x PBS) stock solution:

NaH ₂ PO ₄	26.6 gm
----------------------------------	---------

Na ₂ HPO ₄	289 gm
----------------------------------	--------

NaCl	1064 gm
------	---------

25 distilled H ₂ O	10 L
-------------------------------	------

blocking buffer: 10% FBS/PBS

dilution buffer: 1% BSA/0.05% Tween 20/PBS

-36-

washing buffer: 0.05% Tween 20/PBS

goat anti-human IgE (epsilon chain-specific), unlabeled:
(Tago Catalog # 4104)

human IgE standard: (The Binding Site Catalog # BP094)

5 goat anti-human IgE, HRP-labeled: (Tago Catalog # AHI
0504)

TMB peroxidase substrate: (KPL Catalog # 50-76-02)

peroxidase solution B: (KPL Catalog # 50-65-02)

working substrate solution: mix substrate and Solution

10 B at 1:1 ratio

Immulon II microtiter plates (Dynatech Labs Catalog #
011-010-3455)

IgE ELISA Procedure

Each well of a microtiter plate is coated using 100
15 μ l of a coating buffer containing 2 μ g/ml goat anti-
human IgE.

The coated plate is then incubated overnight at
4°C.

After incubation, each well in the plate is then
20 washed three times with 200 μ l of Tween 20/PBS. After
washing, the non-specific binding sites are blocked with
200 μ l blocking buffer/well for 1 hour at 37°C.

One hundred μ l of samples or standards are then
added to each well; which wells are then incubated over-
25 night at 4°C. After incubation, the samples are tested
with or without dilution. A standard concentration
curve is prepared for each plate using several dilutions
of IgE ranging from 0.1 to 50 ng/ml.

-37-

After overnight incubation, each plate is washed five times with Tween 20/PBS.

One hundred μ l of horseradish peroxidase (HRP) labeled goat anti-human IgE diluted 1:10,000 in dilution buffer is then added to each drained well. The plate is then incubated for 4 hours at 37°C.

The plates are then washed 5 times with Tween 20/PBS and 3 times with water.

One hundred μ l of 3,3',5,5'-tetramethylbenzidine working substrate solution is then added to each well. The plate is then incubated for twenty-five minutes in the dark at room temperature. After incubation the developing reaction is stopped by the addition of fifty μ l of 4 M sulfuric acid.

The absorbency is then read concurrently at 450 and 540 nm. The 540 nm absorbency values are subtracted as background.

Assay for Kd measurement of primate monoclonal anti-human CD23 antibodies

Scatchard Analysis Procedure

1. Radiolabeling Procedure

IODO-BEADS are washed with 100mM Phosphate Buffer, pH 7.4 twice using 1 mL of buffer per 2 beads. The beads are then dried on filter paper.

The two beads are then added to 100 μ l 125 I solution, containing about 1mCi of I, diluted with 200 μ l of the phosphate buffer, and left at room temperature for 5 minutes.

-38-

The antibody (50 μ gs) is added to the preloaded beads. The reaction time for maximal incorporation of radioactivity is 6 minutes.

5 The reaction is stopped by removing the radiolabeled antibody from the reaction vessel.

Gel filtration is then performed to remove excess 125 I or unincorporated 125 I from the radiolabeled antibody solution. This is effected by passing the radiolabeled antibody over a column made up of 1.5mL Sephadex-G25, 10 1.5 mL DEAE Sephadex-A25 and 0.5mL Amberlite. The radiolabeled antibody is eluted off in a total volume of 5 mL at a concentration of about 10 μ g/mL. (Elution Buffer: 1XPBS containing 10% Gelatin, 2% Sodium Azide and 1% BSA).

15 2. Optimization Assay (Direct Binding Study)

The specific activity of the 10 μ g/mL radiolabeled solution is determined by taking a 1 μ l sample and running the sample on a gamma counter.

Example:

- 20 • 1×10^5 cpm/ μ l x 1000 μ l/10 μ g antibody
- 1×10^5 cpm/ μ g antibody
- 1×10^4 cpm/ng antibody
- Molecular wt. of antibody = 75,000 ng/nmole
- Specific activity:
- 25 1×10^4 cpm/ng x 75,000 ng/nmole = 7.5×10^8 cpm/nmole

-39-

The antigen-coated plate is blocked (to eliminate non-specific binding, e.g., with mB7.1-CHO) and the background plate (i.e., Untransfected-CHO) for one hour at room temperature-with 200 μ l/well of blocking buffer (Blocking Buffer: 1xPBS containing 10% Gelatin, 2% Sodium Azide, 1% BSA and 10% FBS).

The plate(s) are then washed, typically ten times by hand with tap water.

The 10 μ g/mL radiolabeled antibody (50 μ ls) is then titrated by two-fold serial dilutions across the plate(s) using a multichannel pipette. Incubate for one hour at room temperature.

The plate(s) are again washed about 6-7 times with 200 μ l/well of wash buffer (Wash Buffer:--1xPBS containing 10% Gelatin and 2% Sodium Azide).

The radio activity counts in each well are then determined by running the wells on a gamma counter.

The optimal radiolabeled antibody concentration is the concentration in which the difference between the specific counts and background counts is at a maximum.

3. Scatchard Analysis of Competition Assay

The 10 μ g/mL radiolabeled solution is diluted to the optimal concentration determined in the Direct Binding experiment.

The antigen-coated plate and the background plate are blocked for one hour at room temperature with 200 μ l/well of blocking buffer.

-40-

The plate(s) are then washed, e.g., about 10 times, by hand with tap water.

The "cold" (no radiolabel) antibody is then titrated by two-fold dilutions in a separate U-bottom microtitre plate. The starting concentration of the "cold" antibody should be at least 100 times greater than that of the optimal radiolabeled antibody concentration.

Example:

- 10 • Optimal Radiolabeled Conc.: 0.5 $\mu\text{g/mL}$
- "Cold" Antibody Conc.: 100 $\mu\text{g/mL}$ (Note: 1:2 titration in the first well will adjust the "cold" antibody concentration to 50 $\mu\text{g/mL}$.)

15 Fifty μl /well of optimal radiolabeled antibody are then added to the wells containing "cold" antibody.

One hundred μl /well of the mixed solution are then transferred to the corresponding wells of the antigen-coated plate, and incubated for one hour at room temperature.

20 Also, it is desirable also that the following controls be effected:

- a) Direct binding of radiolabeled antibody to antigen-coated plate (5 wells),
- b) Direct binding of radiolabeled antibody to back-ground plate (5 wells).

25 After incubation, the plate(s) are washed, e.g., about 6-7 times, with 200 μl /well of wash buffer.

-41-

The radio activity counts in each well are then determined by running the wells on a gamma counter.

These calculations are determined by calculating the specific counts in each well tested by subtracting the background counts from the counts bound to the antigen-coated plate.

4. Calculations for Scatchard Analysis

The Molar Concentration of Bound antibody [B] can then be determined as follows:

10 **Example:** At 50 $\mu\text{g/mL}$ "cold antibody"

Specific counts bound: 4382 cpm

Counts bound in the presence of 50 $\mu\text{g/mL}$ "cold" ab: 215 cpm

Difference: 4382 cpm - 215 cpm = 4167 cpm

15 Specific Activity (radiolabeled ab): 5.54×10^9 cpm/nmole

$4167 \text{ cpm} \div 5.54 \times 10^9 \text{ cpm/nmole} = 7.52 \times 10^{-7} \text{ nmole}$

$7.53 \times 10^{-7} \text{ nmole} \div 0.05 \text{ mL (sample vol.)}$

$= 1.50 \times 10^{-5} \text{ nmole/mL}$

$= 1.50 \times 10^{-8} \mu\text{mole/mL}$

20 [B] = $1.50 \times 10^{-11} \text{ mole/mL (M)}$

Total Molar Concentration [T] is determined as follows:

$50 \mu\text{g/mL} \times 1 \mu\text{mole}/75,000 \mu\text{g} = 6.67 \times 10^{-4} \mu\text{mole/mL}$

$= 6.67 \times 10^{-7} \text{ mmole/mL (M)}$

[T] = $66667 \times 10^{-11} \text{ mmole/mL}$

25 (M)

Free antibody [F] is determined as follows:

-42-

Free Molar Conc. = Total minus Bound

$$\begin{aligned} [F] &= (66667 \times 10^{-11}) - (1.50 \times 10^{-11}) \\ &= 66665.5 \times 10^{-11} \text{ mmole/mL (M)} \end{aligned}$$

Calculate B/F.

- 5 Plot B versus B/F on Cricket Graph software.

Activity and Affinity of Anti-Human CD23
Antibodies According to the Invention

Four of the five isolated primate anti-human CD23
monoclonal antibodies (B3B11, 2C8, 5E8 and 6G5) were
10 found to inhibit IgE production in the above-identified
in vitro assay which measures IgE production by IL4-
hydrocortisone induced peripheral blood mononuclear cell
(PBMC) cultures. These results are shown in Figure 1.
The fifth primate monoclonal anti-human CD23 antibody
15 3G12 was inactive in this assay.

Two of the four primate monoclonal anti-human CD23
antibodies (B3B11 and 2C8) found to be active in this in
vitro assay were found to compete with a commercially
available mouse anti-human CD23 antibody MHM6 (CAKO A/S,
20 Glostrup, Denmark Catalog # M763). (Figure 2, top
panel.) However, in repeated assays these antibodies
were not as potent IgE inhibitors as MHM6 (data not
shown). By contrast, the other primate anti-CD23
monoclonal antibodies (5E8 and 6G5) were found to
25 compete with each other and did not compete with MHM6.
(Figure 2, middle and bottom panels.) Moreover, the
primate anti-human CD23 monoclonal antibody 5E8 was

-43-

found to be a potent inhibitor of IL-4 induced IgE in the *in vitro* assay. (See Figures 1 and 3.)

Modified Hu-SCID-Mouse Model for Human IgE Synthesis
and Measuring the Inhibition of IL-4 Induced IgE
Production by Anti-CD23 Antibodies In Vivo

5

A modified hu-PBMC-SCID mouse model was also developed to detect the effect of the subject antibodies on induced human IgE production *in vivo*. PBMCs obtained from two donors were cultured with IL-4 *in vitro* for two
10 days. PBMCs were pooled and used to reconstitute groups of C.B.-17 SCID mice with and without antibodies. Mice were bled on day 14, 21, 28 and 35 and serum IgG and IgE levels were determined by ELISA. This *in vivo* model was used to assay primate and two different versions of
15 PRIMATIZED® antibodies to CD23 for their ability to inhibit the production of IgE.

A modified SCID mouse model was used because it is known that severe combined immunodeficiency scid/scid (SCID) mice, C.B.-17 (Bosma et al., *Nature*, 301:527
20 (1983)) reconstituted with human peripheral blood mononuclear cells (hu-PBMC-SCID) can produce significant quantities of human immunoglobulins (Ig) (Moiser et al., *Nature*, 335:256 (1988); Moiser et al., *J. Clin. Immunol.*, 10:185 (1990); Abedi et al., *J. Immunol.*,
25 22:823 (1992); and Mazingue et al., *Eur. J. Immunol.*, 21:1763 (1991).) The predominant isotype of human immunoglobulin (Ig) produced in hu-PBMC-SCID mice is IgG. Generally, IgM, IgA and IgE isotypes are found in very low or non-detectable levels except in cases where

-44-

PBMC is obtained from donors with certain autoimmune or allergic disease conditions. It has also been reported that manipulation of hu-PBMC SCID mouse model with certain cytokines may be provided for the generation of significant levels of non-IgG isotypes, including IgE (Kilchherr et al., *Cellular Immunology*, 151:241 (1993); Spiegelberg et al., *J. Clin. Investigation*, 93:711 (1994); and Carballido et al., *J. Immunol.*, 155:4162 (1995)). The hu-PBMC-SCIDs, has been also used to generate antigen specific Ig provided the donor has been primed for the antigen in vivo.

Therefore, the aim of the present inventors was focused on establishing a suitable human IgE producing hu-PBMC-SCID mouse model that could be used to test the efficacy of therapeutic for treatment of IgE related diseases such as allergic disorders, including the subject anti-CD23 antibodies.

Materials and Methods:

The following materials and methods were used in the hu-PBMC-SCID mouse model described below.

SCID mice: C.B-17 scid/scid immunodeficient mice were obtained from Taconic (C.B. -17/IcrTac-scidfDF) and maintained in IDEC Pharmaceuticals' animal facility. Mice were housed in sterilized microbarrier units with sterilized bedding. Animal studies were performed in accordance with the "Guide for the Care and Use of Laboratory Animals" specified by the Committee on Care of Laboratory Animal Resources Commission on Life

-45-

Science-National Research Council (Guide for the Care and Use of Laboratory Animals, DHHS Publ. No. (NIH) 86-23, Bethesda, MD, NIH, 1985).

Human PBMC: PBMCs were isolated from buffy coats
5 obtained from a blood bank by centrifugation through Ficoll-Hypaque (Histopaque-1077) as recommended by the manufacturer (Sigma Diagnostics Catalog # 1077-1). Lymphocyte preparation at the interface of the gradient
10 were harvested and washed three times in Hanks Balanced Salt Solution (HBSS) (Bio-Whittaker Catalog # 10-527F). For each experiment PBMCs were obtained from two separate donors and cultured separately in vitro. PBMCs were resuspended at $1-3 \times 10^6$ cells/ml concentration in
15 HB-Basal medium plus 1% HB101 lyophilized supplement (Irvine Scientific Catalog # T000 & T151) containing 5% FCS plus 1000 IU/ml of IL-4 (Genzyme, Inc. Catalog # 2181-01) and incubated for 48 hours at 37°C with 5% CO₂. After incubation, the cells from different buffy coats were harvested, pooled and used to reconstitute SCID
20 mice.

In Vivo Assay Conditions

Groups of mice (four to five per group) were injected with fifty-sixty $\times 10^6$ lymphocytes in 200-300 μ l volume of HBSS intraperitoneally (i.p.) on day zero.
25 For the groups that received anti-CD23 antibody, on day zero, PBMCs were mixed with anti-CD23 antibody (200 to 400 μ g/mouse) before i.p., injection and the second injection was given on day seven. All mice received

-46-

5000 IU per mouse of IL-4 i.p., between day zero to day five. A group which was not injected with antibody served as the control group. Mice were bled from a retro-orbital vein and the serum was analyzed for IgG and IgE on days fourteen, twenty-one, twenty-eight and thirty-five by ELISA.

Figure 8 shows that the primate anti-human CD23 monoclonal antibody 5E8 is effective in inhibiting IL-4 induced IgE production in vivo in the SCID mouse model.

10 Cloning and Expression of PRIMATIZED® anti-human
 CD23 Monoclonal Antibodies

In order to clone primate immunoglobulin variable domains, Poly A+ RNA was separately isolated from approximately 2×10^6 cells from the primate heterohybridomas secreting the anti-human CD23 monoclonal antibodies 6G5 and 5E8 by using the Micro-FastTrack mRNA isolation Kit (Invitrogen Catalog # K1520-02) according to methods set forth by the manufacturer.

20 The first strand of cDNA was synthesized from the poly A+ RNA by using the cDNA Cycle Kit (Invitrogen Catalog # L1310-01) according to conventional methods.

The light and heavy chain variable regions of 6G5 and 5E8 were then isolated by PCR from cDNA using PCR primers that were selected based upon different consensus families of human immunoglobulins. 5' primers were selected which corresponded to the beginning of the leader sequences of the light and heavy variable region

-48-

(Family 2) was considered more specific because of the relatively greater intensity of the PCR product band.

This PCR product was isolated using a Qiaquick Gel Extraction Kit (Qiagen Catalog # 28704). The purified
5 PCR fragment was digested with Bgl II and Avr II restriction endonucleases, and ligated into the mammalian expression vector N5LG1 which was digested with the same restriction endonucleases. Twenty
10 microliters of the ligation mixture containing the purified PCR product from one fifty microliter PCR reaction, 100 mg N5LG1 vector, two microliters of 10x ligation buffer (NEB Catalog # 202S) and two microliters of T4 ligase (NEB Catalog # 202S), were then incubated at 14°C overnight.

15 The mammalian expression vector N5LG1 contains genetic sequences (e.g., regulatory sequences, coding sequences) which provide for the expression of four separate proteins in a mammalian cell. They are:

20 (i) a partial immunoglobulin light chain with the human lambda light chain constant region and unique restriction endonuclease sites for inserting light chain variable domains;

(ii) a partial immunoglobulin heavy chain with the
25 and human gamma 1 chain constant region coding sequences and unique restriction endonuclease sites for inserting heavy chain variable domains;

(iii) a neomycin phosphotransferase gene used to select for cells that have incorporated the plasmid and

-49-

are resistant to the antibiotic Geneticin (Gibco BRL Catalog # 10131-1209); and

- (iv) a murine dihydrofolate reductase gene (DHFR) which provides for the selection and genomic
- 5 amplification when cells are cultured in the presence of methotrexate (MTX, Sigma Catalog # A-6770) (Reff et al., *Blood*, 83:433-445 (1994)).

After ligation, the mixture was digested using Pme I restriction endonuclease, which digests the parent

10 N5LG1 plasmid, but not the N5LG1 plasmid which has been ligated to the light variable domain of 6G5. After digestion, the mixture was transformed into Epicurian coli® XL1-Blue competent cells (Stratagene Catalog # 200249) as follows.

- 15 One hundred microliters of competent cells were mixed with 10 μ l of the above ligation mixture, set on ice for 30 minutes, then heated at 45°C for 30 seconds. This mixture was placed on ice for 2 minutes, and 900 μ l of SOC, prewarmed to room temperature, was then added.
- 20 (SOC is LB broth Gibco BRL Catalog # 10855-013, plus 0.02 M MgCl₂, 0.02 M MgSO₄ and 0.02 M D-glucose.) After incubation at 37°C for an hour, the mixture was centrifuged at 4000 g for a minute, and 800 μ l of supernatant discarded. The rest of the mixture was
- 25 plated onto a LB agar (Gibco BRL Catalog # 12945-044) dish containing 50 μ g/ml ampicillin (Amp, Gibco BRL Catalog # 13075-015). Plasmid DNA was isolated from individual colonies of *E. coli* that grew on the Amp

-50-

plate by using the Wizard® Miniprep DNA purification system (Promega Catalog # A7510).

5 The isolated plasmid DNA was then characterized by digestion with Bgl II and Avr II followed by agarose gel electrophoresis. An ethidium stained DNA band of 400 bp was indicative of a potential successful cloning of a light chain variable domain.

10 To confirm this was an immunoglobulin light chain variable domain, sequencing was done using the Sequenase 7-Deaza -dGTP DNA Sequencing Kit (USB catalog # 70990) with sequencing primers 607 and GE 108. (See Sequencing Primers in Table 4.)

15 A second independent PCR amplification of the light chain from cDNA of primate monoclonal antibody 6G5 was effected using a 5' primer early leader sequence of lambda light chain family 2 (primer 745) and the 3' J region primer 926. (See Primers for PCR of the lambda light chain variable domain of 6G5 in Tables 1-3.) The isolated PCR product (see technique above) was cloned
20 into TA vector by using the Original TA Cloning(Kit (Invitrogen Catalog # K2000-01). The isolated miniprep DNA (see technique above) was examined under agarose gel electrophoresis after digestion with EcoR I restriction endonuclease. The resultant PCR product comprised in
25 the TA vector was then sequenced (as described previously) using Sp6 and M13(-40) forward primers (See Sequencing primers in Table 4). The resultant light chain sequence was identical to that of light chain from the first PCR. This entire sequence of the light chain

-51-

variable domain of primate monoclonal anti-human CD23 antibody 6G5 is presented below.

Light chain variable region of primate monoclonal antibody anti-human CD23 6G5 Leader

5 Met Ala Trp Thr Leu Leu Leu Val Thr Leu Leu Thr Gln Gly Thr
ATG GCC TGG ACT CTG CTC CTC GTC ACC CTC CTC ACT CAG GGC ACA

-1

Gly Ser Trp Ala

GGA TCC TGG GCT

10 Mature Protein (Numbering is Kabat)

Framework 1

1

9 11

Gln Ser Ala Pro Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly
CAG TCT GCC CCG ACT CAG CCT CCC TCT GTG TCT GGG TCT CCT GGA

15

20

23

Gln Ser Val Thr Ile Ser Cys

CAG TCG GTC ACC ATC TCC TGC

CDR 1

24

27 27A 27B 27C 28

34

20

Thr Gly Thr Ser Asp Asp Val Gly Gly Tyr Asn Tyr Val Ser
ACT GGA ACC AGC GAT GAC GTT GGT GGT TAT AAC TAT GTC TCC

Framework 2

35

40

49

25

Trp Tyr Gln His His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr
TGG TAC CAA CAC CAC CCA GGC AAA GCC CCC AAA CTC ATG ATT TAT

CDR2

50

56

Asp Val Ala Lys Arg Ala Ser

GAT GTC GCT AAG CGG GCC TCA

-52-

Framework 3

57 60 70
 Gly Val Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala
 GGG GTC TCT GAT CGC TTC TCT GGC TCC AAG TCT GGC AAC ACG GCC

5

80

Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr
 TCC CTG ACC ATC TCT GGG CTC CAG GCT GAG GAC GAG GCT GAT TAT

88

Tyr Cys

10

TAC TGT

CDR 3

89 90 95 95A 96 97
 Cys Ser Tyr Thr Thr Ser Ser Thr Leu Leu
 TGT TCA TAT ACA ACC AGT AGC ACT TTG TTA

15

Framework 4

98 100 106 106A 107
 Phe Gly Arg Gly Thr Arg Leu Thr Val Leu Gly
 TTC GGA AGA GGG ACC CGG TTG ACC GTC CTA GGT

2) Cloning the heavy chain variable domain of primate
 monoclonal anti-human CD23 antibody 6G5 by PCR

20

The first PCR amplification of the heavy chain
 variable domain from cDNA of primate monoclonal antibody
 6G5 was performed by using the set of early leader
 sequence primers described supra and the 3' J region
 primer GE244. These primers are in Tables 1-3 infra.
 This reaction resulted in a 350 base PCR product. This
 350 base product (purified as described supra), was di-
 gested with Nhe I and Sal I, and ligated into N5LG1 and

25

-53-

digested with the same endonucleases in the first PCR amplification. The resultant ligation mixture was transformed into host cells using the same techniques for cloning the light chain. Plasmid N5LG1 containing
5 the 350 base PCR product was then isolated and sequenced (using sequencing primers 266 and 268). (These Sequencing primers are set forth in Table 4.)

Sequencing revealed that the PCR product contained only part of the heavy variable domain and comprised a
10 deletion in its amino terminus (Sequence began at framework 2, codon 36).

A second independent PCR reaction was conducted to amplify and isolate the heavy chain variable domain of primate monoclonal antibody 6G5 using a 5' early leader
15 sequence primer for family 1 (MB1503) and a 3' J' region primer GE244. (These primers are also contained in Tables 1-3.) The resultant PCR product was then cloned into the N5LG1 using the same techniques described supra. Its sequence was found to be identical to the
20 first PCR product.

Therefore, in order to clone the whole heavy variable domain of 6G5 including the missing 5' terminus a new longer 3' primer (MB1533) which included the CDR3 and framework 4 regions of the 6G5 heavy variable chain
25 was then used in a third independent PCR reaction with the family 1 5' primer (MB1503). (These primers are also contained in Tables 1-3.)

After PCR, a larger 420 base PCR product was observed on the agarose gel. This PCR product was

-54-

isolated as described previously, and cloned into a TA vector. The resultant PCR product contained in the TA vector was then sequenced. Sequencing revealed that this DNA contained the whole heavy variable domain and
5 that the 3' part was identical to that of previously cloned partial heavy chain variable domain from the first two PCR reactions.

A fourth independent PCR was performed using the same primers as the third PCR amplification. This
10 resulted in a PCR product which was isolated and cloned into the TA vector as described previously. The sequence of the fourth independent PCR product was found to be identical to that obtained in the third PCR amplification. This sequence, which comprises the heavy
15 chain variable domain of primate monoclonal anti-human CD23 antibody 6G5, is presented below.

Heavy chain variable region of primate monoclonal
antibody anti-human CD23 6G5

Leader

20 Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg
ATG AAA CAC CTG TGG TTC TTC CTC CTC CTG GTG GCA GCT CCC AGA

-1

Trp Val Leu Ser
TGG GTC CTG TCC

-55-

Mature Protein (Numbering is Kabat)Framework 1

1 10
 Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Val Val Lys Pro Ser
 5 CAG CTG CAG CTG CAG GAG TCG GGC CCA GGA GTG GTG AAG CCT TCG
 20 30
 Glu Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Gly Ser Val Ser
 GAG ACC CTG TCC CTC ACC TGC GCT GTC TCT GGT GGC TCT GTC AGC

CDR 1

10 31 35 35a
 Ser Ser Asn Trp Trp Thr
 AGT AGT AAC TGG TGG ACC

Framework 2

36 40 49
 15 Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly
 TGG ATC CGC CAG CCC CCA GGG AAG GGA CTG GAG TGG ATT GGA

CDR2

50 52 52A 53 60
 Arg Ile Ser Gly Ser Gly Gly Ala Thr Asn Tyr Asn Pro Ser Leu
 20 CGT ATC TCT GGT AGT GGT GGG GCC ACC AAC TAC AAC CCG TCC CTC
 65
 Lys Ser
 AAG AGT

Framework 3

CDR 3

Framework 4

3) Construction of mammalian expression vectors

To construct the N5LG4P + 6G5 vector, both the
30 light and heavy chain variable domains were isolated

-57-

from N5LG1 + 6G5 by digestion of Bgl II and Avr II, and
Nhe I and Sal I respectively. The mammalian expression
vector N5LG4P vector is identical to the N5LG1 vector
described above, except the human gamma 1 was replaced
5 with a human gamma 4 constant region containing a
mutation of a serine to a proline in the hinge region to
increase stability of the immunoglobulin and improve
pharmacokinetics *in vivo* ("P" mutation). The light
chain variable domain was cloned in the plasmid first
10 and the heavy chain variable domain was cloned into the
vector containing the light chain variable domain using
techniques previously described. This mammalian
expression vector was named N5LG4P + 6G5.

15 **B. Construction of the plasmids N5KG4P + 5E8, N5KG1
+5E8, N5KG4P + 5E8N-, and N5KG1 + 5E8N-**

**1. Cloning the light chain variable domain of primate
monoclonal anti-human CD23 antibody 5E8 by PCR**

The first PCR reaction of the light chain variable
domain from 5E8 cDNA was carried out using a set of
20 kappa early leader sequence primers and the 3' J region
primer GE204. (See primers for PCR of the kappa light
chain variable domain of 5E8 in Tables 1-3). A 420 base
PCR product was obtained. The isolated 420 base PCR
product was digested with Bgl II and BsiW I restriction
25 endonucleases, cloned into the mammalian expression
vector N5KG4P and sequenced using GE108 and 377 primers
(which are contained in Table 4). The mammalian
expression vector N5KG4P is identical to the vector

-58-

N5LG4P except it contains the human kappa light chain
 constraint region in place of the human lambda light
 chain constant region. Sequencing of this 420
 polynucleotide DNA revealed that it contains the entire
 5 kappa light chain variable domain.

A second independent PCR of the light chain
 variable region was performed using the 5' family 1
 primer GE201 and the 3' primer GE204. (See primers for
 PCR of the kappa light chain variable domain of 5E8 in
 10 Tables 1-3). The isolated PCR product was cloned into
 the TA vector (using methods previously described) and
 sequenced using Sp6 and T7 promoter primers. Sequencing
 revealed that this PCR product was identical to that
 obtained from the first PCR. The entire sequence of the
 15 light chain variable domain of primate monoclonal
 anti-human CD23 antibody 5E8 is presented below.

Light chain variable region of primate monoclonal
antibody anti-human CD23 5E8

Leader

20 Met Asp Met Arg Val Pro Ala Gln Leu Leu Gly Leu Leu Leu Leu
 ATG GAC ATG AGG GTC CCC GCT CAG CTC CTG GGG CTC CTT CTG CTC

-1

Trp Leu Pro Gly Ala Arg Cys
 TGG CTC CCA GGT GCC AGA TGT

25 Mature Protein (Numbering is Kabat)

Framework 1

1 10
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val

-59-

GAC ATC CAG ATG ACC CAG TCT CCA TCT TCC CTG TCT GCA TCT GTA

20 23

Gly Asp Arg Val Thr Ile Thr Cys

GGG GAC AGA GTC ACC ATC ACT TGC

5

CDR 1

24 30 34

Arg Ala Ser Gln Asp Ile Arg Tyr Tyr Leu Asn

AGG GCA AGT CAG GAC ATT AGG TAT TAT TTA AAT

Framework 2

10 35 40 49

Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr

TGG TAT CAG CAG AAA CCA GGA AAA GCT CCT AAG CTC CTG ATC TAT

CDR2

50 56

15 Val Ala Ser Ser Leu Gln Ser

GTT GCA TCC AGT TTG CAA AGT

Framework 3

57 60 70

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe

20 GGG GTC CCA TCA AGG TTC AGC GGC AGT GGA TCT GGG ACA GAG TTC

80

Thr Leu Thr Val Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr

ACT CTC ACC GTC AGC AGC CTG CAG CCT GAA GAT TTT GCG ACT TAT

88

25 Tyr Cys

TAC TGT

CDR 3

89 90 97

Leu Gln Val Tyr Ser Thr Pro Arg Thr

30 CTA CAG GTT TAT AGT ACC CCT CGG ACG

-60-

Framework 4

98 100 107
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
TTC GGC CAA GGG ACC AAG GTG GAA ATC AAA

5 2) Cloning the heavy chain variable domain of primate
monoclonal anti-human CD23 antibody 5E8 by PCR

10 The first PCR of the heavy chain variable domain of
5E8 was performed using a set of 5' early leader heavy
chain sequence primers and the 3' primer GE210. (See
primers for PCR of the heavy chain variable domain of
6G5 and 5E8 in Table 1). A 420 base PCR product
appeared in the family 3 primer reaction. The PCR
product was purified and then digested with Nhe I and
Sal I and cloned into the mammalian expression vector
15 N5KG4P vector (as described previously). The PCR
product was sequenced using the 268 and 928 primers.
(See sequencing primers in Table 4.)

20 A second independent PCR of the heavy chain
variable domain of 5E8 was performed using the family 3
5' primer GE207 and the 3' primer GE210. (See primers
for PCR of the heavy chain variable domain of 6G5 and
5E8 in Tables 1-3). The isolated PCR product was cloned
into a TA vector using the same techniques previously
described and sequenced by using Sp6 and T7 primers.
25 Sequencing revealed that the TAC at codon 91 had been
changed into TGC.

In order to determine the appropriate codon at 91,
a third independent PCR was performed using the same
primers as the second PCR (see above). The PCR product

-61-

was again cloned into a TA vector and sequenced using Sp6 and T7 primers. The sequence was found to be identical to the heavy chain variable sequence obtained in the first PCR. Therefore, the TGC at position 91 in the second independent PCR product is apparently the result of an error introduced during PCR. This entire sequence of the heavy chain variable domain of primate monoclonal anti-human CD23 antibody 5E8 is presented below.

10 Heavy chain variable region of primate monoclonal
antibody anti-human CD23 5E8

Leader

Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Pro Leu Leu Lys
ATG GAG TTT GGG CTG AGC TGG GTT TTC CTT GTT CCT CTT TTG AAA
15 -1
Gly Val Gln Cys
GGT GTC CAG TGT

Mature Protein (Numbering is Kabat)

Framework 1

20	1									10							
	Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Ala	Lys	Pro	Gly		
	GAG	GTG	CAG	CTG	GTG	GAG	TCT	GGG	GGC	GGC	TTG	GCA	AAG	CCT	GGG		
					20											30	
	Gly	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Arg	Phe	Thr		
25	GGG	TCC	CTG	AGA	CTC	TCC	TGC	GCA	GCC	TCC	GGG	TTC	AGG	TTC	ACC		

CDR 1

31					35	35a	35b
Phe	Asn	Asn	Tyr	Tyr	Met	Asp	
TTC	AAT	AAC	TAC	TAC	ATG	GAC	

Framework 2

5

CDR2

10

Framework 3

20

CDR 3

25

Framework 4

103							110		113	
Trp	Gly	Gln	Gly	Val	Leu	Val	Thr	Val	Ser	Ser
TGG	GGC	CAG	GGA	GTC	CTG	GTC	ACC	GTC	TCC	TCA

-63-

3) Construction of mammalian expression vectors

The heavy variable domain in N5KG4P was digested with Nhe I and Sal I, purified, and cloned into N5KG4P which contains the light chain variable domain of 5E8.

5 This plasmid was then digested with the restriction endonucleases as previously described. This resulted in a vector containing both the light and heavy variable domain of 5E8. This vector was named N5KG4P + 5E8. The heavy and light variable domains of N5KG4P + 5E8 were
10 then both inserted into the mammalian expression vector N5KG1 to create the N5KG1+ 5E8 vector.

4) Alteration of an amino acid in the heavy chain variable region of primate monoclonal antibody 5E8 by site specific mutagenesis and construction of mammalian expression vectors

15 Based upon the sequence of 5E8 heavy variable domain, there is a potential glycosylation site of the immunoglobulin at asparagine codon 75. This potential glycosylation site corresponds to a conserved
20 asparagine-linked glycosylation motif having the following tripeptide sequence: (Asp) - (Any amino acid except proline) - (Serine or threonine). Therefore, a glycosylation mutant of 5E8, which would be unable to be glycosylated at this position because of modification of
25 this glycosylation motif, was generated by replacing the asparagine codon 75 with a lysine (which is found in many human immunoglobulins at this position). Site specific mutagenesis was effected by the following methods.

-64-

A first PCR was done using N5KG4P + 5E8 as a template and a 3' primer (corresponding to codon 71 to 79) and which contains a mutation at codon 75 (AAC changed to AAG, Primer MB1654, and a 5' primer at the beginning of the leader sequence (Primer MB1650). (See PCR Primers Used for the Generation of a Glycosylation Mutant of the Heavy Chain Variable Region 5E8 set forth in Table 5).

A second PCR was performed on the same template by using a 5' primer (corresponding to codon 71 to 79) containing the same mutation (Primer MB1653) and a 3' primer from the end of framework 4 (Primer MB1651) (See PCR Primers Used for the Generation of a Glycosylation Mutant of the Heavy Chain Variable Region of 5E8 in Table 5.)

These two PCR products were isolated and mixed in equal molar ratios. A third independent PCR was then carried out by using the mixture of the first and second PCR products as a template with a 5' primer used in the first PCR (MB1650) and a 3' primer used in the second PCR (MB 1651). (See PCR Primers Used for the Generation of a Glycosylation Mutant of the Heavy Chain Variable Region in Table 5.) The PCR product obtained in third PCR was found to contain the heavy variable domain coding region of 5E8 wherein the asparagine 75 had been changed to lysine.

The third PCR product was purified, digested with restriction endonucleases Sal I and Nhe I, and cloned into the N5KG4P containing the light variable domain

only. The PCR product was sequenced to confirm that it comprised the mutant heavy variable domain. This mammalian expression plasmid was named N5KG4P + 5E8N-.

Table 1

	NAME	<u>Light chain Vκ-early leader 5' (BqI II)</u>								FAMILY
15					-22 -21 -20 -19 -18		-17 -16	-15 -14		
	GE201	5'	AT CAC	<u>AGA TCT</u>	CTC ACC	ATG GAC	ATG AGG GTC	CCC GCT	CAG 3'	1
	GE200	5'	AT CAC	<u>AGA TCT</u>	CTC ACC		ATG AGG CTC	CCT GCT	CAG 3'	2
	GE202	5'	AT CAC	<u>AGA TCT</u>	CTC ACC		ATG GAA (A/G) CC	CCA GC(T/G)	CAG	3'
		3								
20	GE203	5'	AT CAC	<u>AGA TCT</u>	CTC ACC		ATG GTG TTG	CAG ACC	CAG GTC	
		3'4								

25

GE204 5' GG TGC AGC CAC CGT AGC TTT GAT (C/T)TC CA(G/C)

CTT 3'

113 112 111 110 109 108 107 106 105 104 103

Primers for PCR of the lambda light chain variable domain of 6G5

30

NAME	<u>Light chain V1-early leader 5' (Bq1 II)</u>	FAMILY
744	5' AT CAC <u>AGA TCT</u> CTC ACC ATG (G/A)CC TG(G/C) TCC CCT CT 3'	

-66-

745 5' AT CAC AGA TCT CTC ACC ATG GCC TGG (A/G)CT C(T/C)G CT 3'
 2
 910 5' AT CAC AGA TCT CTC ACC ATG GC(A/C) TGG A(T/C)C CCT CTC 3'
 3

5

Light chain V1-3' primer (Avr II)

110 109 108 107 106 105 104
 926 5' (AC)10 CTT GGG CTG ACC TAG GAC GGT 3'

Table 3

Primers for PCR of the heavy chain
variable domains from 6G5 and 5E8

10

NAME Heavy chain-early leaders 5' (Sal I)Family

15

-20 -19 -18 -17 -16 -15
 MB1503 5' GCG ACT AAG TCG ACC ATG GAC TGG ACC TGG 3' 1
 MB1502 5' GCG ACT AAG TCG ACC ATG AAA CAC CTG TGG 3'
 2,4
 GE207 5' GCG ACT AAG TCG ACC ATG GAG TTT GGG CTG AGC 3' 3
 GE208 5' GCG ACT AAG TCG ACC ATG GGG TCA ACC GCC ATC 3' 5
 GE209 5' GCG ACT AAG TCG ACC ATG TCT GTC TCC TTC CTC 3' 6

Heavy chain-3' primer (Nhe I)

20

120 119 118 117 116 115 114 113 112 111
 110
 GE244 5' GC CAG GGG GAA GAC CGA TGG GCC CTT GGT GCT AGC TGA GGA GAC GG
 3'
 GE210 5' GA TGG GCC CTT GGT GCT AGC TGA GGA GAC GG
 25 3'

MB1533 5'
 GGT

GGT GCT AGC TGA GGA GAC

109 108 107 106 105 104 103 101 100 99
 GAC CAG GAC TCC CTG GCC CCA GAA GCC TAG 3'

30

Table 4Sequencing Primers

Sp6 primer

5' AT TTA GGT GAC ACT ATA

3'

-67-

	M13 (-40) Forward Primer	5' GTT TTC CCA GTC ACG A	3'
	T7 Promoter Primer	5' AT ATA CGA CTC ACT ATA GGG	3'
	GE 108 Primer	5' CCG TCA GAT CGC CTG GAG ACG CCA	3'
5	377 Primer	5' GCA GTT CCA GAT TTC AAC TG	3'
	607 PRIMER	5' CCA GGC CAC TGT CAC GGC TTC	3'
	266 PRIMER	5' CAG AGC TGG GTA CGT CCT CA	3'
	268 PRIMER	5' GCC CCC AGA GGT GCT CTT GG	3'
	876 PRIMER	5' ACA CAG ACC CGT CGA CAT GG	3'
10	928 PRIMER	5' GCT CTC GGA GGT GCT CCT GG	3'

Table 5

PCR Primers Used for the Generation of a Glycosylation
Mutant of the Heavy Chain Variable Region of 5E8

15		Sal I	-20 -19 -18 -17 -16	
	MB 1650	5' ACA GAC CCG TCG ACC ATG GAG TTT GGG CTG	3'	
		Nhe I		
		118 117 116 115 114 113 112 111 110		
20	MB 1651	5' CCC CTT GGT GCT AGC TGA GGA GAC GGT	3'	
		71 72 73 74 75 76 77 78 79		
	MB 1653	5' AGA GAG AAC GCC AAG AAC ACA CTG TTT	3'	
		79 78 77 76 75 74 73 72 71		
	MB 1654	5' AAA CAG TGT GTT CTT GGC GTT CTC TCT	3'	

25 C) Construction of gamma-3 vectors

Numerous methods exist for conversion of murine antibodies to chimeras in which the heavy and light chain constant regions are substituted with human

-68-

versions or in which all but the CDRs (complementary determining regions) are substituted with their human equivalents. (See Biochem. J. 281:317, 1992; Proc. Nat. Acad. Sci. USA 86:10029, 1989; Methods Enzymol. 178:515, 5 1989; Cancer Res. 51:181, 1991; Biotechniques 7:360, 1989; J. Immunol. 143:3589, 1989; Int. J. Cancer 44:424, 1989; Proc. Nat. Acad. Sci. USA 86:3833, 1989).

Further, the previous sections specifically demonstrate that construction of vectors for expression 10 of PRIMATIZED® gamma-1 and gamma-4 antibodies may be accomplished by amplifying the DNA encoding the light and heavy chain variable regions using PCR, and cloning these regions into an expression vector or vectors encoding the appropriate human constant region domains. 15 Thus, it should be clear that similar constructs may be made which encode other human constant region domains, so long as appropriate mammalian expression vectors are available which also contain cloning sites which allow insertion of the amplified variable region DNA from the 20 primate antibodies.

It should also be apparent that the PCR primers used to amplify the variable region DNA may be designed to accommodate various restriction cloning sites depending on the vector used.

25 Vectors encoding the constant region domain from human IgG3 are available in the art, and may be used for constructing the PRIMATIZED® antibodies of the present invention. For instance, Co et al. have used separate vectors expressing human light and heavy chain constant

-69-

regions for constructing chimeric and humanized antibodies, and provide heavy chain vectors for both human gamma-1 and gamma-3. For cloning the variable domain regions of the antibody of interest into these
5 vectors, an *Xba*I restriction site is conveniently located just before the constant regions in the $J_{\kappa 4}$ and the $J_{\mu 3}$ intronic segments for the light and heavy chains, respectively (Co et al., 1996, Cancer Res. 56: 1118-1125; Co et al., 1992, J. Immunol. 148: 1149-1154).

10 Thus, by designing PCR primers which incorporate *Xba*I restriction sites, or sites which create the same single stranded overhangs as the *Xba*I restriction enzyme (i.e. *Nhe*I, *Spe*I), the variable regions from a primate antibody may be associated with the human gamma-
15 3 constant region domain using the vectors described in Co et al. Alternatively, linkers or adaptors may be used to facilitate cloning.

It is also possible to construct a cDNA version of the human gamma-3 constant region using DNA synthesis
20 techniques and insert it into the N5KG1 vectors described herein in place of the human gamma-1 constant region between the *Nhe*I and *Bam*HI sites. Depending on which restriction sites are most convenient for cloning the particular variable region of interest, there are
25 also other gamma-3 vectors which have been described in the art, and any of these may be used to construct and express the gamma-3 antibodies of the present invention. (See, for example, Parren et al., 1992, J. Immunol. 148(3): 695-701; Steplewski et al., 1988, Proc. Natl.

-70-

Acad. Sci. USA 85: 4852-4856; and U.S. Patent No. 4,975,369, herein incorporated by referenced).

D) Variations of PRIMATIZED® Antibodies

The present invention also encompasses PRIMATIZED®
5 antibodies containing mutations, substitutions or deletions of the constant region. Such mutations may be constructed using site-directed mutagenesis techniques as described above for the glycosylation mutant, which are well-known techniques for those of skill in the art.

10 The mutated antibodies of the present invention are designed with the purpose of creating a desired change in the level of therapeutic efficiency, i.e. in FcR binding. However, it should be understood that any mutation in the constant region of the antibodies should
15 not alter the basic effector functions as mediated by the gamma-1 or gamma-3 constant region domains. It may also be possible to alter other subclasses of gamma antibodies by mutagenesis such that they have similar effector functions as an antibody containing a gamma-1
20 or a gamma-3 domain. Such antibodies are also encompassed by the present invention.

For example, the regions of the IgG constant region involved in FcR binding and interaction with the C1q complement component have been characterized, and
25 mutations have been identified which either increase or decrease binding affinity. As disclosed in U.S Patent 5,648,260, herein incorporated by reference, changing Leu 235 to Glu in the human IgG3 constant region

-71-

destroys the interaction of the mutant for the human Fc gamma R1 receptor. Furthermore, mutations on adjacent or close sites in the hinge link region (i.e. replacing residues 234, 236 or 237 by Ala) indicate that

5 alterations in residues 234, 235, 236 and 237 at least affect affinity for the Fc gamma R1 receptor.

Similarly, in U.S. Patent 5,348,876, also incorporated by reference, it was shown that by decreasing the length of the hinge region of the human

10 IgG3 constant region and altering the amino acid sequence of this region, C1q binding and thus complement mediated cytolysis were further improved. In fact, the variants bound more C1q than wild type IgG3 and much more than IgG1.

15 Thus, it is clear from the art that mutations may be used to create therapeutic antibodies with decreased affinities for human Fc receptors, perhaps for the treatment of more mild medical conditions. In addition, mutations may be identified which increase effector

20 function activity, thereby leading to stronger versions for therapeutic use. It should be recognized that manipulations of gene sequence to create alterations in drug efficiency are envisioned, and well within the spirit and scope of the present invention.

-72-

E) Expression of PRIMATIZED® Antibodies
in Chinese Hamster Ovary Cells

In order to isolate the PRIMATIZED® antibodies, the vectors encoding the antibodies were expressed in

5 Chinese Hamster Ovary cells using the following protocol.

A large scale plasmid DNA was purified using the WIZARD® Maxipreps DNA Purification System (Promega Catalog # A7421). The purified DNA was digested with
10 Ssp I and BspLU11 I, precipitated with ethanol once, and resuspended in sterile TE.

Purified, endonuclease restricted plasmid DNA was then introduced into Chinese hamster ovary (CHO) dihydrofolate reductase minus DG44 cells using
15 electroporation. The electroporation technique used is described below.

Approximately 1.6×10^8 CHO cells were spun in an appropriate size sterile Corning tube for one minute at 1000 RPM. The media was removed and the cells were
20 washed in fifteen milliliters of sterile ice cold SBS (sterile sucrose buffered solution is 272 mM sucrose, 7 mM sodium phosphate pH 7.4, 1 mM $MgCl_2$) and spun for 5 minutes at 1000 RPM. The SBS was removed and cells were suspended using fresh ice cold sterile SBS at a cell
25 concentration of 1×10^7 cells were per ml and left on ice for 15 minutes. The BTX 600 electroporator was turned on and preset at 230 volts, with the maximum voltage knobs being set at 500 volts/capacitance & resistance.

-73-

The capacitance was set at 400 microfaradays and the resistance was set at 13 ohms (setting R1).

Plasmid DNA (4 μ g DNA or 2 μ g DNA) and 0.4 ml of cells (4×10^6 cells) were then placed in BTX 0.4 ml cuvettes (BTX Catalog # 620). The cells were shocked by placing the cuvette into the BTX 600 stand and pressing the automatic charge & pulse button. Approximately 20 separate electroporations were performed with each mammalian expression plasmid.

After shocking, the cuvettes were left at ambient temperature for fifteen minutes. The cells and DNA were from each cuvette were resuspended in 20 ml of CHO-SSFMII containing no hypoxanthine or thymidine (Gibco BRL Catalog # 31033-012) to which HT supplement (100X supplement is 10 mM sodium hypoxanthine, 1.6 mM thymidine Gibco BRL Catalog # 11067-014) had been added. The cells from a single electroporated cuvette were then plated into a 96 well plates (200 μ l/well) and placed into a 37°C CO₂ incubator. Selection was started two or three days later by changing the media to the above media with the addition of 400 mg/ml of Geneticin® (G418, Gibco BRL Catalog # 10131-019). The cells were grown at 37°C and the cell media were changed every 3-5 days. After sixteen days G418 resistant clones appeared in the wells and the supernatant was assayed for antibody expression by ELISA. The highest expressing clones were then expanded individually. Monoclonal antibodies were purified as described below.

-74-

Immunoglobulin ELISA

Plates (Immulon 2, Dynatech Laboratories, Inc. Catalog # 011-010-3455) are coated overnight at 4°C with 200 ng unlabeled goat anti-human IgG antibody at 100
5 μ l/well. This is effected using twenty milliliters of unlabeled goat anti-human IgG/10 mls Coating Buffer/plate (Boehringer Mannheim Ab Catalog # 605 400). (1:500 dilution of ~ 1mg/ml stock.) The coating buffer is then removed from the plates and dried using a paper
10 towel. One hundred microliters of a dilution buffer/well is then added.

Antibody solutions and standards (100 ng/ml - 2.5 ng/ml) are then added in duplicate at 100 μ l/well directly to the 100 ml dilution buffer. The antibody
15 solutions and standards are contained in dilution buffer. The resultant solutions are then incubated for at least 1 hour at 37°C.

After incubation, the contents of each plate are removed and the plates are washed with tap water five
20 times. The plates are then dried on a paper towel.

After drying of the plates, a second antibody is then added at 100 μ l/well. This second antibody is either goat anti-human Kappa-HRPO: added at 1/10,000 dilution or 1 μ l Ab/10 mls dilution buffer/plate,
25 available from Southern Biotechnology Associates, Inc. Catalog # 2060-05 or a goat anti-human Lambda-HRPO; used at 1/20,000 dilution or 1 μ l Ab/20 mls dilution buffer/2 plates (available from Southern Biotechnology Associates, Inc. Catalog # 2070-05).

-75-

The antibody and contents of the plate are allowed to incubate for one hour at 37°C. After incubation the contents of each plate are removed. The plates are again washed five time with tap water, and the washed
5 plates are dried. To the dried plates is then added HRPO substrate (TMB Microwell - two component) in an amount of 100 µl/well. (Five milliliters of TMB Peroxidase Substrate + five milliliters of Peroxidase Solution B/plate (Kirdgaard and Perry Labs, TMB
10 Microwell two component reagents Catalog # 50-76-00).

The reaction is stopped by the addition of one hundred microliters of 2M H₂SO₄ to each well when the weakest standard (2.5 ng/ml) is visible over background. The optical density of wells in plates is then read
15 using a plate reader, e.g., Molecular Devices Emax precision microplate reader set at wavelength: OD 450 and OPT2 (OD 540).

ELISA BUFFERS

Coating Buffer

20 Sodium Carbonate 0.8 gram / liter
Sodium Bicarbonate 1.55 gram / liter
Adjust pH to 9.5 with ~1ml 1N HCl

Dilution Buffer

0.5% Nonfat Dry Milk in PBS plus 0.01% Thimerosal
25 (5 gm/L) (100 mg/L)

Examples of ELISA values obtained using the above-described assay are set forth below.

-76-

	<u>Standard</u>	<u>OD 450</u>	<u>OD450</u>	<u>Average</u>
	100 ng/ml	0.805	0.876	0.841
	50 ng/ml	0.395	0.472	0.434
	25 ng/ml	0.213	0.252	0.233
5	10 ng/ml	0.089	0.105	0.097
	5 ng/ml	0.054	0.055	0.055
	2.5 ng/ml	0.031	0.035	0.033
	0 ng/ml	0.004	0.006	0.005

STANDARDS IN DILUTION BUFFER

- 10 Appropriate dilution of stock AB (sterile filtered in normal saline, protein determination by OD) to give 1mg/ml

EXAMPLE:

- 15 Chimeric monkey/human anti-CD4 (CE9.1) is 4.18 mg/ml
- 24 μ l of above into 76 μ l Dilution Buffer is 1 mg/ml
- 50 μ l Stock Ab (1 mg/ml) into 450 μ l Dilution Buffer (D.B.) is 100 μ g/ml
- 20 50 μ l of above mixture into 450 μ l D.B. is 10 μ g/ml
- 200 μ l of above mixture into 1.8 mls D.B. is 1 μ g/ml
- 1 ml of above mixture into 9 mls D.B. is 100 ng/ml
- 25 *
- 5 ml of above mixture into 5 ml D.B. is 50 ng/ml *
- 5 ml of above mixture into 5 ml D.B. is 25 ng/ml *
- 4 ml of above mixture into 6 ml D.B. is 10 ng/ml *

-77-

5 ml of above mixture into 5 ml D.B. is 5 ng/ml *

5 ml of above mixture into 5 ml D.B. is 2.5 ng/ml *

* Standards used in the ELISA

Antibody purification by Protein A

5 Procedure

The culture supernatant is centrifuged to remove cells and debris. The centrifuge is then filtered through a 0.2 μ m filter. A protein A sepharose Fast flow column (recombinant protein A Sepharose Fast floe) 10 (Pharmacia Biotech Catalog # 71-5000-09) is then prepared and equilibrated using PBS (pH 7.4).

The supernatant is loaded on the column at an appropriate flow rate (e.g., 2 ml/min). After loading, the column is washed with 10 column volume of PBS (pH 15 7.4). The antibody is eluted from the column using an elution buffer (0.2M acetic acid, 0.1 M glycine pH 3.5) at 1 ml/min flow rate. One milliliter fractions/tube including 100 μ l of Tris are then collected. A spectrophotometer absorbance reading is then taken at 20 280 nm. The antibody fractions are then collected and dialyzed against PBS (pH 7.9) overnight. The dialysate is then sterilized by filtration through a 0.22 μ m membrane and stored at -20°C.

Assay Results

25 The PRIMATIZED® human gamma-4 anti-human CD23 antibodies which are described supra, were purified and assayed for induced IgE inhibitory activity in vitro.

-78-

These results are contained in Figures 3 and 5. This was effected using the *in vitro* IL-4 IgE assay described *supra*.

These assay results surprisingly indicated that
5 both human gamma-4 anti-human CD23 antibodies were not as active as the corresponding primate anti-human CD23 antibodies, i.e., they did not significantly inhibit induced IgE production *in vitro*.

However, because primate 5E8 and p5E8G4P have a
10 potential asparagine linked glycosylation site in the heavy chain variable region, the effects of glycosylation at this site were investigated. (It was found that both these antibodies contain N-linked oligosaccharides at this site. (Data not shown.))
15 Therefore, in order to prevent glycosylation, the asparagine in the glycosylation site was changed to a lysine in order to eliminate carbohydrate addition. This mutated antibody was named p5E8G4PN-. Assay results demonstrated that this antibody behaved
20 identically to p5E8G4P in the IL-4 IgE assay (see Figure 3) and also exhibited an identical apparent affinity Kd for human CD23. (See Figure 4.) Therefore, these results indicated that the difference in IgE inhibition observed from the 5E8 gamma 4 PRIMATIZED® antibody in
25 comparison to primate 5E8 antibody was not attributable to glycosylation differences.

The three primate antibodies (p5E8G4P, p5E8G4PN-, and pGG5G4P) were then expressed as human gamma-1 versions using substantially the same methodology. All

-79-

three human gamma-1 anti-human CD23 antibodies, respectively designated p5E8G1, p5E8G1N- and pGG5G1, were found to be active in the *in vitro* IL-4/IgE assay (Figures 3 and 5).

5 p5E8G1 was found to be statistically more suppressive than p5E8G4P at a concentration of 0.3 μ g/ml (P[T,t] one tail + 0.0055) and at 3 μ g/ml (p[T<t] one tail + 0.0019). In addition, p5E8G1N- is statistically more suppressive than p5E8G4PN- at both 0.3 μ g/ml
10 (p[T<t] one tail + 0.0392) and at 3 μ g/ml (p[T<t] one tail + 0.0310) (Figure 3).

Similarly, p6G5G1 completely inhibited induced IgE production at 3 mg/ml, while p6G5G4P did not. (These results are in Figure 5).

15 Thus, these results suggested that an active Fc region, in particular that of human gamma-1, is significant for induced IgE inhibition by anti-human CD23 antibodies. These results also suggest that human anti-CD23 antibodies containing human gamma-3 constant regions
20 will be significant for induced IgE inhibition because a gamma-3 constant region binds to the same Fc γ R receptors that gamma-1 binds to, and will likely mediate the same result.

EXAMPLE 2

25 To confirm our hypothesis as to the involvement of the Fc effector portion in IgE inhibition of anti-human CD23 antibodies, a third primate antibody, designated 2C8, also shown to inhibit IgE in *in vitro*) was

-80-

converted to a $F(ab')_2$. IgE inhibitory activity was determined using the same IL-4/IgE assay described previously.

Materials

- 5 The following materials were used in this example.
 ImmunoPure $F(ab')_2$ Preparation Kit (Pierce Catalog #
44888)
 digestion buffer: 20 mM sodium acetate buffer, pH
4.5
10 0.1 M citric acid, pH 3.0 (adjust pH with NaOH)
 0.1% sodium azide in water
 dialysis tubing; 50,000 MW cutoff (Spectra Por
Catalog # 132 128)
 shaking water bath capable of maintaining 37°C
15 polystyrene culture tubes, 17 x 100 mm (Fisher
Catalog # 14-956-6B)
 BCA protein assay (Pierce Catalog # 23224)
 Centricon-50 concentrators (Amicon Catalog # 4225).

Equilibration of Immobilized Pepsin

- 20 0.25 milliliters of the 50% slurry of Immobilized
Pepsin is added to a 17 x 100 mm test tube (0.125 ml of
gel). Four milliliters of digestion buffer are then
added. The pepsin is then separated from the buffer
using the serum separator. The buffer is then discarded
25 and the wash procedure repeated using another four
milliliters of buffer. The immobilized pepsin is then
resuspended in 0.5 ml of digestion buffer.

-81-

Preparation of Immobilized Protein A Column

Protein A AffinityPak[®] columns and ImmunoPure Binding and Elution buffers are brought to room temperature.

5 Preparation of 2C8 F(ab')₂ Fragments

2C8 F(ab')₂ fragments are prepared by methods well known in the antibody art. The inventors elected to use a commercially available kit, ImmunoPure F(ab')₂ Preparation Kit (Pierce Catalog # 44888), using the
10 manufacturer's protocols.

Ten milligrams of lyophilized 2C8 antibody were dissolved in one milliliter of a digestion buffer (20 mM sodium acetate buffer, pH 4.5). One milliliter of the antibody containing sample was then added to a tube con-
15 taining immobilized pepsin.

The antibody and immobilized pepsin were then incubated for four hours in a high speed shaker water bath at 37°C (at high speed), taking care to maintain the mixing constant during the incubation.

20 The resultant solubilized F(ab')₂ and Fc fragments and the undigested IgGs were then recovered from the immobilized pepsin gel using a serum separator. The crude digest is then decanted into a clean tube.

In order to enhance recovery of F(ab')₂ fragments,
25 the immobilized pepsin desirably is then washed with 1.5 of milliliters of the ImmunoPure IgG binding buffer. The wash is then added to the crude digest.

-82-

The antibody fragments were then recovered using a protein A column. This is effected by opening an immobilized protein A column. Care is taken to avoid air bubbles from being drawn into the gel. The storage solution (which contains 0.02% sodium azide) is
5 discarded.

The immobilized protein A column was then equilibrated using twelve milliliters of binding buffer (contained in ImmunoPure Preparation Kit). The column
10 was then transferred to a 17 x 100 mm test tube contained in the kit (labeled "F(ab')₂") to collect eluate.

Three milliliters of the crude digest was then applied to a column and are allowed to flow completely
15 into the gel. The use of AffinityPak™ columns is desirable as these columns stop flowing automatically when the level reaches the top frit.

The column is then washed using six milliliters of binding buffer. The eluate which contains F(ab')₂ fragments was then collected. This eluate also contains
20 small Fc fragments that can no longer bind protein A (which are not bound to the Protein A column). However, the substantial portion thereof was eliminated by dialysis.

25 Dialysis was effected by taking the F(ab')₂ containing eluate and dialyzing the eluate against pH 7.4 phosphate buffered saline, using dialysis tubing with a molecular weight cut-off of 50,000 so as to

-83-

eliminate the small Fc fragment containments (Spectra Pur. Catalog # 132 128).

This resulted in a F(ab')₂ fraction having an optical density of 280 nm of 0.707 (6 ml). After
5 dialysis and concentration with Centricon-50 concentrators (Amicon Catalog # 4225), the 2C8 F(ab')₂ product was assayed for protein content using a BCA protein assay (Pierce Catalog # 23224). The protein content was found to be 3.76 mg per milliliter.

10 The 2C8 F(ab)₂'s were assayed for IgE inhibitory activity and were found to be substantially incapable of inhibiting IgE production in the same in vitro assays described previously. These results are contained in Figure 6. In fact, the F(ab')₂ was found to antagonize
15 the suppressive effects of induced IgE on the monoclonal antibody 2C8. These results are in Figure 7.

EXAMPLE 3

The PRIMATIZED® gamma 1 and gamma 4P versions of primate monoclonal 6G5 were both evaluated for their
20 effect on inhibition of induced IgE production in vivo in the SCID mouse model described previously. p5E8G1N- was found to be as efficient as primate 5E8 in inhibiting induced IgE. (See Figures 8 and 9). While neither primate 6G5 nor the primatized p6G5G4P were
25 effective at inhibiting induced IgE in vivo, primatized p6G5G1 inhibited induced IgE production. (See Figures 9 and 10.). These results further substantiate our conclusion that an active Fc region is significant to

-84-

the ability of an anti-human CD23 antibody to effectively inhibit induced IgE production.

Proposed Mechanism

Although the results of the present invention conclusively demonstrate that an active Fc region is significant to the ability of an anti-human CD23 antibody to effectively inhibit induced IgE production, the molecular mechanism has not been elucidated. However, several hypotheses may be made.

Firstly, it may be that the anti-CD23 antibodies of the present invention function to trigger a similar signal transduction pathway as is apparently triggered by cross-linking B cell receptor with anti-BCR gamma-1 antibodies. It has been hypothesized that the down-regulation of antigen receptor signaling in this case results from coligation of Fc gamma RII and surface Ig (B cell receptor) on the same B cell, leading to down regulation of Ig expression. (D'Ambrosia et al., 1995, *Science*, 268:293-297; Ono et al., 1997, *Cell* 90: 293-301). Indeed, CD23 is upregulated on the surface of IgE-expressing B cells, so it is possible that coligation of CD23 and the FcγRII-B receptor via the gamma-1 constant region results in a similar signal transduction pathway.

Alternatively, inhibition of induced IgE expression may be occurring through cross-linking of surface IgE on B cells at the same time as the Fc region interacts with an appropriate FcγR receptor on another cell type, i.e.

-85-

a killer T cell, which may then "instruct" the B cell to undergo apoptosis, or lead to cell death in some other manner (i.e. phagocytosis). For instance, U.S. Patent No. 5,543,144, herein incorporated by reference, 5 proposes a similar mechanism for inhibiting IgE-expressing B cells with anti-IgE antibodies. As discussed therein, antibodies of certain IgG subclasses, such as mouse IgG2a and human IgG1 and IgG3, can mediate ADCC (Antibody Dependent Cellular Cytotoxicity) carried 10 out by certain Fc receptor-bearing phagocytic leukocytes. For example, OKT3, a mouse IgG2a monoclonal antibody specific for human T cell surface antigen (which was the first monoclonal antibody product approved by the FDA for marketing as a therapeutic 15 agent) is used in patients to provide rapid depletion of T cells in the blood and to induce an immunosuppressed state (for kidney transplantation). (Russell, P. S. et.al, Transpl. Proc. 17:39-41 (1985)). OKT3, at a dosage of 5 mg/day/subject, can completely deplete 20 circulating T cells. The monoclonal antibodies described in U.S. Patent 5,543,144, especially in the form of mouse gamma 2a antibodies or human or humanized antibodies bearing human gamma-1 or gamma-3 chains, are proposed to deplete IgE-expressing B cells by the ADCC 25 mechanism in a similar manner.

But whatever the actual molecular mechanism for inhibiting IgE expression using anti-CD23 antibodies may be, it is clear that the Fc region, and accordingly effector function, of anti-CD23 antibodies are important

-86-

considerations. As discussed previously, since complement is not present in the in vitro assays of the present invention, the phenomenon likely involves one or more FcγR receptors. Once the relevant molecular components are identified, as well as molecules internal to the cells involved which are involved in signal transduction pathways, it will be possible to design other therapeutics which may also be used to inhibit induced IgE expression.

10

Utility

Because of their ability to effectively inhibit IgE production, the subject anti-human CD23 antibodies which comprise human gamma-1 constant domains, and those that may also be constructed containing gamma-3, are effective in treating any disease wherein inhibition of IgE production is therapeutically desirable. Such diseases include by way of example allergic diseases, autoimmune diseases and inflammatory disease.

15

Specific conditions which are potentially treatable by administration of the subject anti-CD23 human gamma-1/ gamma-3 constant domain containing antibodies include the following:

20

Allergic bronchopulmonary aspergillosis; Allergic rhinitis and conjunctivitis autoimmune hemolytic anemia; Acanthosis nigricans; Allergic contact dermatitis; Addison's disease; Atopic dermatitis; Alopecia areata; Alopecia universalis; Amyloidosis; Anaphylactoid purpura; Anaphylactoid reaction; Aplastic anemia; Angioedema, hereditary; Angioedema, idiopathic; Ankylosing

25

-87-

spondylitis; Arteritis, cranial; Arteritis, giant cell;
Arteritis, Takayasu's; Arteritis, temporal; Asthma;
Ataxia-telangiectasia; Autoimmune oophoritis; Autoimmune
orchitis; Autoimmune polyendocrine failure; Behcet's
5 disease; Berger's disease; Buerger's disease;
bronchitis; Bullous pemphigus; Candidiasis, chronic
mucocutaneous; Caplan's syndrome; Post-myocardial
infarction syndrome; Post-pericardiotomy syndrome;
Carditis; Celiac sprue; Chagas's disease;
10 Chediak-Higashi syndrome; Churg-Strauss disease; Cogan's
syndrome; Cold agglutinin disease; CREST syndrome;
Crohn's disease; Cryoglobulinemia; Cryptogenic fibrosing
alveolitis; Dermatitis herpetiformis; Dermatomyositis;
Diabetes mellitus; Diamond-Blackfan syndrome; DiGeorge
15 syndrome; Discoid lupus erythematosus; Eosinophilic
fasciitis; Episcleritis; Erythema elevatum diutinum;
Erythema marginatum; Erythema multiforme; Erythema
nodosum; Familial Mediterranean fever; Felty's syndrome;
Fibrosis pulmonary; Glomerulonephritis, anaphylactoid;
20 Glomerulonephritis, autoimmune; Glomerulonephritis,
post-streptococcal; Glomerulonephritis,
post-transplantation; Glomerulopathy, membranous;
Goodpasture's syndrome; Graft-vs.-host disease;
Granulocytopenia, immune-mediated; Granuloma annulare;
25 Granulomatosis, allergic; Granulomatous myositis;
Grave's disease; Hashimoto's thyroiditis; Hemolytic
disease of the newborn; Hemochromatosis, idiopathic;
Henoch-Schoenlein purpura; Hepatitis, chronic active and
chronic progressive; Histiocytosis_X; Hypereosinophilic

-88-

- syndrome; Idiopathic thrombocytopenic purpura; Job's syndrome; Juvenile dermatomyositis; Juvenile rheumatoid arthritis (Juvenile chronic arthritis); Kawasaki's disease; Keratitis; Keratoconjunctivitis sicca;
- 5 Landry-Guillain-Barre-Strohl syndrome; Leprosy, lepromatous; Loeffler's syndrome; lupus; Lyell's syndrome; Lyme disease; Lymphomatoid granulomatosis; Mastocytosis, systemic; Mixed connective tissue disease; Mononeuritis multiplex; Muckle-Wells syndrome;
- 10 Mucocutaneous lymph node syndrome; Mucocutaneous lymph node syndrome; Multicentric reticulohistiocytosis; Multiple sclerosis; Myasthenia gravis; Mycosis fungoides; Necrotizing vasculitis, systemic; Nephrotic syndrome; Overlap syndrome; Panniculitis; Paroxysmal
- 15 cold hemoglobinuria; Paroxysmal nocturnal hemoglobinuria; Pemphigoid; Pemphigus; Pemphigus erythematosus; Pemphigus foliaceus; Pemphigus vulgaris; Pigeon breeder's disease; Pneumonitis, hypersensitivity; Polyarteritis nodosa; Polymyalgia rheumatic;
- 20 Polymyositis; Polyneuritis, idiopathic; Portuguese familial polyneuropathies; Pre-eclampsia/eclampsia; Primary biliary cirrhosis; Progressive systemic sclerosis (Scleroderma); Psoriasis; Psoriatic arthritis; Pulmonary alveolar proteinosis; Pulmonary fibrosis,
- 25 Raynaud's phenomenon/syndrome; Reidel's thyroiditis; Reiter's syndrome, Relapsing polychondritis; Rheumatic fever; Rheumatoid arthritis; Sarcoidosis; Scleritis; Sclerosing cholangitis; Serum sickness; Sezary syndrome; Sjogren's syndrome; Stevens-Johnson syndrome; Still's

-89-

disease; Subacute sclerosing panencephalitis;
Sympathetic ophthalmia; Systemic lupus erythematosus;
Transplant rejection; Ulcerative colitis;
Undifferentiated connective tissue disease; Urticaria,
5 chronic; Urticaria, cold; Uveitis; Vitiligo;
Weber-Christian disease; Wegener's granulomatosis;
Wiskott-Aldrich syndrome.

Of these, the preferred indications treatable or
presentable by administration of anti-CD23 antibodies
10 include allergic rhinitis and conjunctivitis, atopic
dermatitis; eczema; Job's syndrome, asthma; allergic
conditions; and chronic inflammatory diseases and
conditions, including CLL chronic lymphocytic leukemia,
typically characterized by high levels of membrane CD23
15 and high circulating levels of sCD23 (Sarfart et al.,
Blood 71: 94-98 (1988)).

The amount of antibody useful to produce a
therapeutic effect can be determined by standard
techniques well known to those of ordinary skill in the
20 art. The antibodies will generally be provided by
standard technique within a pharmaceutically acceptable
buffer, and may be administered by any desired route.
Because of the efficacy of the presently claimed anti-
bodies and their tolerance by humans it is possible to
25 administer these antibodies repetitively in order to
combat various diseases or disease states within a
human.

One skilled in the art would be able, by routine
experimentation, to determine what an effective,

-90-

non-toxic amount of antibody would be for the purpose of effecting allergic diseases and inflammatory conditions. Generally, however, an effective dosage will be in the range of about 0.05 to 100 milligrams per kilogram body weight per day.

The antibodies of the invention may be administered to a human or other animal in accordance with the aforementioned methods of treatment in an amount sufficient to produce such effect to a therapeutic or prophylactic degree. Such antibodies of the invention can be administered to such human or other animal in a conventional dosage form prepared by combining the antibody of the invention with a conventional pharmaceutically acceptable carrier or diluent according to known techniques. It will be recognized by one of skill in the art that the form and character of the pharmaceutically acceptable carrier or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables.

The route of administration of the antibody of the invention may be oral, parenteral, by inhalation or topical. The term parenteral as used herein includes intravenous, intramuscular, subcutaneous, rectal, vaginal or intraperitoneal administration. The intravenous form of parenteral administration is generally preferred.

The daily parenteral and oral dosage regimens for employing compounds of the invention to prophylactically

-91-

or therapeutically induce immunosuppression will generally be in the range of about 0.05 to 100, but preferably about 0.5 to 10, milligrams per kilogram body weight per day.

5 The antibody of the invention may also be administered by inhalation. By "inhalation" is meant intranasal and oral inhalation administration. Appropriate dosage forms for such administration, such as an aerosol formulation or a metered dose inhaler, may
10 be prepared by conventional techniques. The preferred dosage amount of a compound of the invention to be employed is generally within the range of about 10 to 100 milligrams.

15 The antibody of the invention may also be administered topically. By topical administration is meant non-systemic administration and includes the application of an antibody (or fragment thereof) compound of the invention externally to the epidermis, to the buccal cavity and instillation of such an antibody into the
20 ear, eye and nose, and where it does not significantly enter the blood stream. By systemic administration is meant oral, intravenous, intraperitoneal and intramuscular administration. The amount of an antibody required for therapeutic or prophylactic effect will, of
25 course, vary with the antibody chosen, the nature and severity of the condition being treated and the animal undergoing treatment, and is ultimately at the discretion of the physician. A suitable topical dose of an antibody of the invention will generally be within

-92-

the range of about 1 to 100 milligrams per kilogram body weight daily.

Formulations

While it is possible for an antibody or fragment thereof to be administered alone, it is preferable to present it as a pharmaceutical formulation. The active ingredient may comprise, for topical administration, from 0.001% to 10% w/w, e.g., from 1% to 2% by weight of the formulation, although it may comprise as much as 10% w/w but preferably not in excess of 5% w/w and more preferably from 0.1% to 1% w/w of the formulation.

The topical formulations of the present invention, comprise an active ingredient together with one or more acceptable carrier(s) therefor and optionally any other therapeutic ingredients(s). The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of where treatment is required, such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose.

Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a

-93-

bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent. The resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 90°-100°C for half an hour. Alternatively, the solution may be sterilized by filtration and transferred to the container by an aseptic technique. Examples of bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%). Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.

Lotions according to the present invention include those suitable for application to the skin or eye. An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops. Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.

Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided

-94-

or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy basis. The basis may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; 5 a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives, or a fatty acid such as stearic or oleic acid together with an alcohol such as propylene glycol or macrogels. The formulation may incorporate any 10 suitable surface active agent such as an anionic, cationic or non-ionic surface active such as sorbitan esters or polyoxyethylene derivatives thereof. Suspending agents such as natural gums, cellulose 15 derivatives or inorganic materials such as siliceous silicas, and other ingredients such as lanolin, may also be included.

It will be recognized by one of skill in the art that the optimal quantity and spacing of individual 20 dosages of an antibody or fragment thereof of the invention will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular animal being treated, and that such optimums can be determined by conventional 25 techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of an antibody or fragment thereof of the invention given per day for a defined number of days, can be ascertained by those skilled in the art

-95-

using conventional course of treatment determination tests.

Without further elaboration, it is believed that one skilled in the art can, using the preceding
5 description, utilize the present invention to its fullest extent. The following are, therefore, to be construed as merely illustrative examples and not a limitation of the scope of the present invention in any way.

10

Capsule Composition

A pharmaceutical composition of this invention in the form of a capsule is prepared by filling a standard two- piece hard gelatin capsule with 50 mg. of an antibody or fragment thereof of the invention, in
15 powdered form, 100 mg. of lactose, 32 mg. of talc and 8 mg. of magnesium stearate.

Injectable Parenteral Composition

A pharmaceutical composition of this invention in a form suitable for administration by injection is
20 prepared by stirring 1.5k by weight of an antibody or fragment thereof of the invention in 10k by volume propylene glycol and water. The solution is sterilized by filtration.

Ointment Composition

25 Antibody or fragment thereof of the invention 10 g.
White soft paraffin to 100.0 g.

-96-

The antibody or fragment thereof of the invention is dispersed in a small volume of the vehicle to produce a smooth, homogeneous product. Collapsible metal tubes are then filled with the dispersion.

5 Topical Cream Composition

Antibody or fragment thereof of the invention 1.0g.

Polawax GP 200 20.0 g.

Lanolin Anhydrous 2.0 g.

White Beeswax 2.5 g.

10 Methyl hydroxybenzoate 0.1 g.

Distilled Water to 100.0 g.

The polawax, beeswax and lanolin are heated together at 60°C. A solution of methyl hydroxybenzoate is added and homogenization is achieved using high speed stirring. The temperature is then allowed to fall to 15 SOOC. The antibody or fragment thereof of the invention is then added and dispersed throughout, and the composition is allowed to cool with slow speed stirring.

Topical Lotion Composition

20 Antibody or fragment thereof of the invention 1.0g.

Sorbitan Monolaurate 0.6 g. Polysorbate 20 0.6 g.

Cetostearyl Alcohol 1.2 g. Glycerin 6.0 g.

Methyl Hydroxybenzoate 0.2 g.

Purified Water B.P. to 100.00 ml. (B.P. = British
25 Pharmacopeia)

The methyl hydroxybenzoate and glycerin are dissolved in 70 ml. of the water at 75°C. The sorbitan

-97-

monolaurate, polysorbate 20 and cetostearyl alcohol are melted together at 75°C and added to the aqueous solution. The resulting emulsion is homogenized, allowed to cool with continuous stirring and the antibody or fragment thereof of the invention is added as a suspension in the remaining water. The whole suspension is stirred until homogenized.

Eye Drop Composition

Antibody or fragment thereof of the invention 0.5g.
Methyl Hydroxybenzoate 0.01 g.
Propyl Hydroxybenzoate 0.04 g.
Purified Water B.P. to 100.00 ml.

The methyl and propyl hydroxybenzoates are dissolved in 70 ml. purified water at 75°C and the resulting solution is allowed to cool. The antibody or fragment thereof of the invention is then added, and the solution is sterilized by filtration through a membrane filter (0.022 Am pore size), and packed aseptically into suitable sterile containers.

Composition for Administration by Inhalation

For an aerosol container with a capacity of 15-20 ml: mix 10 mg. of an antibody or fragment thereof of the invention with 0.2-0.5k of a lubricating agent, such as polysorbate 85 or oleic acid, and disperse such mixture in a propellant, such as freon, preferably in a combination of (1,2 dichlorotetrafluoroethane) and difluorochloromethane and put into an appropriate

-98-

aerosol container adapted for either intranasal or oral inhalation administration. Composition for Administration by Inhalation For an aerosol container with a capacity of 15-20 ml: dissolve 10 mg. of an
5 antibody or fragment thereof of the invention in ethanol (6-8 ml.), add 0.1-0.2k of a lubricating agent, such as polysorbate 85 or oleic acid; and disperse such in a propellant, such as freon, preferably in combination of (1-2 dichlorotetrafluoroethane) and
10 difluorochloromethane, and put into an appropriate aerosol container adapted for either intranasal or oral inhalation administration.

Parenteral Administrable Antibody Compositions

The antibodies and pharmaceutical compositions of
15 the invention are particularly useful for parenteral administration, i.e., subcutaneously, intramuscularly or intravenously. The compositions for parenteral administration will commonly comprise a solution of an antibody of the invention or a cocktail thereof
20 dissolved in an acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers may be employed, e.g., water, buffered water, 0.4k saline (normal saline), 0.3% glycine, and the like. The use of normal saline is preferred. These solutions are sterile
25 and generally free of particulate matter. These solutions may be sterilized by conventional, well-known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as

-99-

required to approximate physiological conditions such as pH adjusting and buffering agents, etc. The concentration of the antibody or fragment thereof of the invention in such pharmaceutical formulation can vary widely. Such concentrations will be selected primarily based on fluid volumes, viscosities, etc., according to the particular mode of administration selected.

Generally suitable intravenous concentrations range from about one to one hundred milligrams per milliliter.

Thus, a pharmaceutical composition of the invention for intravenous injection could comprise 10 mL normal saline containing 40-50 mg of an anti-human CD23 antibody of the invention. Methods for preparing parenterally administrable compositions are well-known or will be apparent to those skilled in the art, and are described in more detail in, for example, *Remington's Pharmaceutical Science*, 15th ed., Mack Publishing Company, Easton, Pennsylvania, hereby incorporated by reference herein.

The antibodies of the invention can be lyophilized for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective with conventional immune globulins and art-known lyophilization and reconstitution techniques can be employed.

Depending on the intended result, the pharmaceutical composition of the invention can be administered for prophylactic and/or therapeutic treatments. In therapeutic application, compositions

-100-

are administered to a patient already suffering from a disease, in an amount sufficient to cure or at least partially arrest the disease and its complications. In prophylactic applications, compositions containing the present antibodies or a cocktail thereof are administered to a patient not already in a disease state to enhance the patient's resistance.

Single or multiple administrations of the pharmaceutical compositions can be carried out with dose levels and pattern being selected by the treating physician. In any event, the pharmaceutical composition of the invention should provide a quantity of the subject anti-CD23 antibodies sufficient to effectively treat the patient.

It should also be noted that the antibodies of this invention may be used for the design and synthesis of either peptide or non-peptide compounds (mimetics) which would be useful in the same therapy as the antibody. See, e.g., Saragovi et al., *Science*, 253:792-795 (1991).

From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without diverting from the scope of the invention. Accordingly, the invention is not limited by the appended claims.

-101-

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: REFF, Mitchell E.
KLOETZER, William S.
5 NAKAMURA, Takehiko

(ii) TITLE OF INVENTION: GAMMA-1 ANTI-HUMAN CD23 MONOCLONAL
ANTIBODIES AND USE THEREOF AS THERAPEUTICS

(iii) NUMBER OF SEQUENCES: 35

10 (iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
(B) STREET: P.O. Box 1404
(C) CITY: Alexandria
(D) STATE: Virginia
15 (E) COUNTRY: United States
(F) ZIP: 22313-1404

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
20 (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: US 08/803,085
(B) FILING DATE: 20-FEB-1997
25 (C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

-102-

- (A) NAME: Teskin, Robin L.
- (B) REGISTRATION NUMBER: 35,030
- (C) REFERENCE/DOCKET NUMBER: 012712-353

(ix) TELECOMMUNICATION INFORMATION:

- 5 (A) TELEPHONE: (703) 836-6620
- (B) TELEFAX: (703) 836-2021

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 390 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- 15 (A) NAME/KEY: CDS
- (B) LOCATION: 1..390

(ix) FEATURE:

- (A) NAME/KEY: mat_peptide
- (B) LOCATION: 58..390

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATG GCC TGG ACT CTG CTC CTC GTC ACC CTC CTC ACT CAG GGC ACA GGA

48

Met Ala Trp Thr Leu Leu Leu Val Thr Leu Leu Thr Gln Gly Thr Gly

-19

-15

-10

-5

-103-

TCC TGG GCT CAG TCT GCC CCG ACT CAG CCT CCC TCT GTG TCT GGG TCT

96

Ser Trp Ala Gln Ser Ala Pro Thr Gln Pro Pro Ser Val Ser Gly Ser

-1

1

5

10

5 CCT GGA CAG TCG GTC ACC ATC TCC TGC ACT GGA ACC AGC GAT GAC GTT

144

Pro Gly Gln Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Asp Asp Val

15

20

25

GGT GGT TAT AAC TAT GTC TCC TGG TAC CAA CAC CAC CCA GGC AAA GCC

10

192

Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln His His Pro Gly Lys Ala

30

35

40

45

CCC AAA CTC ATG ATT TAT GAT GTC GCT AAG CGG GCC TCA GGG GTC TCT

240

15 Pro Lys Leu Met Ile Tyr Asp Val Ala Lys Arg Ala Ser Gly Val Ser

50

55

60

GAT CGC TTC TCT GGC TCC AAG TCT GGC AAC ACG GCC TCC CTG ACC ATC

288

Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile

20

65

70

75

TCT GGG CTC CAG GCT GAG GAC GAG GCT GAT TAT TAC TGT TGT TCA TAT

336

Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Cys Ser Tyr

80

85

90

25 ACA ACC AGT AGC ACT TTG TTA TTC GGA AGA GGG ACC CGG TTG ACC GTC

384

Thr Thr Ser Ser Thr Leu Leu Phe Gly Arg Gly Thr Arg Leu Thr Val

95

100

105

-104-

CTA GGT

390

Leu Gly

110

5 (2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 423 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

10

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..423

15

(ix) FEATURE:

(A) NAME/KEY: mat_peptide

(B) LOCATION: 58..423

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

20

ATG AAA CAC CTG TGG TTC TTC CTC CTC CTG GTG GCA GCT CCC AGA TGG

48

Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp

-19

-15

-10

-5

-105-

GTC CTG TCC CAG CTG CAG CTG CAG GAG TCG GGC CCA GGA GTG GTG AAG

96

Val Leu Ser Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Val Val Lys

-1 1

5

10

5 CCT TCG GAG ACC CTG TCC CTC ACC TGC GCT GTC TCT GGT GGC TCT GTC

144

Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Gly Ser Val

15

20

25

AGC AGT AGT AAC TGG TGG ACC TGG ATC CGC CAG CCC CCA GGG AAG GGA

10 192

Ser Ser Ser Asn Trp Trp Thr Trp Ile Arg Gln Pro Pro Gly Lys Gly

30

35

40

45

CTG GAG TGG ATT GGA CGT ATC TCT GGT AGT GGT GGG GCC ACC AAC TAC

240

15 Leu Glu Trp Ile Gly Arg Ile Ser Gly Ser Gly Gly Ala Thr Asn Tyr

50

55

60

AAC CCG TCC CTC AAG AGT CGA GTC ATC ATT TCA CAA GAC ACG TCC AAG

288

Asn Pro Ser Leu Lys Ser Arg Val Ile Ile Ser Gln Asp Thr Ser Lys

20

65

70

75

AAC CAG TTC TCC CTG AAC CTG AAC TCT GTG ACC GCC GCG GAC ACG GCC

336

Asn Gln Phe Ser Leu Asn Leu Asn Ser Val Thr Ala Ala Asp Thr Ala

80

85

90

25 GTG TAT TAC TGT GCC AGA GAT TGG GCC CAA ATA GCT GGA ACA ACG CTA

384

Val Tyr Tyr Cys Ala Arg Asp Trp Ala Gln Ile Ala Gly Thr Thr Leu

95

100

105

-106-

GGC TTC TGG GGC CAG GGA GTC CTG GTC ACC GTC TCC TCA

423

Gly Phe Trp Gly Gln Gly Val Leu Val Thr Val Ser Ser

110

115

120

5 (2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 387 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

10

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..387

15

(ix) FEATURE:

(A) NAME/KEY: mat_peptide

(B) LOCATION: 67..387

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATG GAC ATG AGG GTC CCC GCT CAG CTC CTG GGG CTC CTT CTG CTC TGG

20

48

Met Asp Met Arg Val Pro Ala Gln Leu Leu Gly Leu Leu Leu Leu Trp

-22

-20

-15

-10

-107-

CTC CCA GGT GCC AGA TGT GAC ATC CAG ATG ACC CAG TCT CCA TCT TCC

96

Leu Pro Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ser Ser

-5

-1 1

5

10

5

CTG TCT GCA TCT GTA GGG GAC AGA GTC ACC ATC ACT TGC AGG GCA AGT

144

Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser

15

20

25

10

CAG GAC ATT AGG TAT TAT TTA AAT TGG TAT CAG CAG AAA CCA GGA AAA

192

Gln Asp Ile Arg Tyr Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys

30

35

40

GCT CCT AAG CTC CTG ATC TAT GTT GCA TCC AGT TTG CAA AGT GGG GTC

240

15

Ala Pro Lys Leu Leu Ile Tyr Val Ala Ser Ser Leu Gln Ser Gly Val

45

50

55

CCA TCA AGG TTC AGC GGC AGT GGA TCT GGG ACA GAG TTC ACT CTC ACC

288

20

Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr

60

65

70

GTC AGC AGC CTG CAG CCT GAA GAT TTT GCG ACT TAT TAC TGT CTA CAG

336

Val Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln

75

80

85

90

25

GTT TAT AGT ACC CCT CGG ACG TTC GGC CAA GGG ACC AAG GTG GAA ATC

384

Val Tyr Ser Thr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile

95

100

105

-108-

AAA

387

Lys

5 (2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 411 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

10 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..411

15 (ix) FEATURE:

(A) NAME/KEY: mat_peptide

(B) LOCATION: 58..411

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

ATG GAG TTT GGG CTG AGC TGG GTT TTC CTT GTT CCT CTT TTG AAA GGT

20 48

Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Pro Leu Leu Lys Gly

-19

-15

-10

-5

GTC CAG TGT GAG GTG CAG CTG GTG GAG TCT GGG GGC GGC TTG GCA AAG

Val Gln Cys Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ala Lys

10

144

Pro Gly Gly Ser Leu Arg Leu Trp Cys Ala Ala Ser Gly Phe Arg Phe

25

Thr Phe Asn Asn Tyr Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln

45

240

60

288

75

336

90

384

105

-110-

CAG GGA GTC CTG GTC ACC GTC TCC TCA

411

Gln Gly Val Leu Val Thr Val Ser Ser

110

115

5 (2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 41 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

10

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATCACAGATC TCTCACCATG GACATGAGGG TCCCCGCTCA G

41

15 (2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 35 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

20

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

-111-

ATCACAGATC TCTCACCATG AGGCTCCCTG CTCAG

35

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- 5
- (A) LENGTH: 35 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

10 (ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 24
- (D) OTHER INFORMATION: /note= "Nucleotide 24 is N wherein
N = A/G."

15 (ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 32
- (D) OTHER INFORMATION: /note= "Nucleotide 32 is N wherein
N = T/G."

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

ATCACAGATC TCTCACCATG GAANCCCCAG CNCAG

35

(2) INFORMATION FOR SEQ ID NO:8:

-112-

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

ATCACAGATC TCTCACCATG GTGTTGCAGA CCCAGGTC

38

10 (2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 24
- (D) OTHER INFORMATION: /note= "Nucleotide 24 is N wherein
N = C/T."

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 29
- (D) OTHER INFORMATION: /note= "Nucleotide 29 is N wherein

-113-

N = G/C."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GGTGCAGCCA CCGTAGCTTT GATNTCCAN

29

5 (2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 34 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

10 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION: 21

15 (D) OTHER INFORMATION: /note= "Nucleotide 21 is N wherein

N = G/A."

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION: 26

20 (D) OTHER INFORMATION: /note= "Nucleotide 26 is N wherein

N = G/C."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

ATCACAGATC TCTCACCATG NCCTGNTCCC CTCT

34

-114-

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 34 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 27
- (D) OTHER INFORMATION: /note= "Nucleotide 27 is N wherein
N = A/G."

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 31
- (D) OTHER INFORMATION: /note= "Nucleotide 31 is N wherein
N = T/C."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

ATCACAGATC TCTCACCATG GCCTGGNCTC NGCT

34

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 base pairs

-115-

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

5

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 23
- (D) OTHER INFORMATION: /note= "Nucleotide 23 is N wherein

N = A/C."

10

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 29
- (D) OTHER INFORMATION: /note= "Nucleotide 29 is N wherein

N = T/C."

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

ATCACAGATC TCTCACCATG GCNTGGANCC CTCTC

35

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

20

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

-116-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CTTGGGCTGA CCTAGGACGG T

21

(2) INFORMATION FOR SEQ ID NO:14:

5 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GCGACTAAGT CGACCATGGA CTGGACCTGG

30

(2) INFORMATION FOR SEQ ID NO:15:

15 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

-117-

GCGACTAAGT CGACCATGAA ACACCTGTGG

30

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

5

- (A) LENGTH: 33 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GCGACTAAGT CGACCATGGA GTTTGGGCTG AGC

33

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

15

- (A) LENGTH: 33 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GCGACTAAGT CGACCATGGG GTCAACCGCC ATC

33

-118-

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

GCGACTAAGT CGACCATGTC TGTCTCCTTC CTC

10 33

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 46 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

GCCAGGGGGA AGACCGATGG GCCCTTGGTG CTAGCTGAGG AGACGG

20 46

-119-

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

GATGGGCCCT TGGTGCTAGC TGAGGAGACG G

10

31

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 51 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

GGTGCTAGCT GAGGAGACGG TGACCAGGAC TCCCTGGCCC CAGAAGCCTA G

20

51

(2) INFORMATION FOR SEQ ID NO:22:

-120-

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

ATTTAGGTGA CACTATA

17

10 (2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

GTTTTCCCAG TCACGA

16

20 (2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs

-121-

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

ATATACGACT CACTATAGGG

20

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

CCGTCAGATC GCCTGGAGAC GCCA

24

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

-122-

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

GCAGTTCAG ATTCAACTG

5

20

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

10

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

CCAGGCCACT GTCACGGCTT C

15

21

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

20

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

-123-

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

CAGAGCTGGG TACGTCCTCA

20

5 (2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

10 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

GCCCCCAGAG GTGCTCTTGG

20

15 (2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

20 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

-124-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

ACACAGACCC GTCGACATGG

20

(2) INFORMATION FOR SEQ ID NO:31:

5 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

GCTCTCGGAG GTGCTCCTGG

20

(2) INFORMATION FOR SEQ ID NO:32:

15 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

-125-

ACAGACCCGT CGACCATGGA GTTTGGGCTG

30

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

5

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

CCCCTTGGTG CTAGCTGAGG AGACGGT

27

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:

15

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

AGAGAGAACG CCAAGAACAC ACTGTTT

27

-126-

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

5 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

AAACAGTGTG TTCTTGGCGT TCTCTCT

10

27

-127-

WHAT IS CLAIMED IS:

1. An anti-human CD23 monoclonal antibody comprising a constant region that binds to human Fc gamma receptors and inhibits IgE expression.
- 5 2. The anti-human CD23 monoclonal antibody of Claim 1, which comprises a primate antigen binding portion.
3. The anti-human CD23 monoclonal antibody of Claim 1, which is either a human gamma-1 or a human gamma-3 monoclonal antibody.
- 10 4. The anti-human CD23 monoclonal antibody of Claim 1, which comprises a rodent antigen binding portion.
5. The anti-human CD23 antibody of Claim 1, which is a humanized antibody.
6. The anti-human CD23 monoclonal antibody of Claim 1,
15 which inhibits IgE expression *in vitro*.
7. The anti-human CD23 monoclonal antibody of Claim 6, which inhibits IL-4 induced IgE expression by B cells *in vitro*.
8. The anti-human CD23 monoclonal antibody of Claim 1,
20 which inhibits IL-4 induced IgE expression *in vivo*.

-128-

9. The anti-human CD23 monoclonal antibody of Claim 1, having a binding affinity ranging from 0.01 nM to 1000 nM.
10. The anti-human CD23 monoclonal antibody of Claim 1,
5 having a CD23 binding affinity of at least 5nM.
11. The anti-human CD23 monoclonal antibody of Claim 9, having a CD23 binding affinity of at least 100nM.
12. The anti-human CD23 antibody of Claim 1, wherein the variable domains are derived from 5E8, 6G5 or 2C8.
- 10 13. The anti-human CD23 antibody of Claim 1, which is capable of inhibiting the binding of monoclonal anti-human CD23 antibody 5E8 or 6G5 to CD23.
14. A pharmaceutical composition containing an anti-human CD23 antibody according to Claim 1.
- 15 15. A pharmaceutical composition containing an anti-human CD23 antibody according to Claim 2.
16. A pharmaceutical composition containing an anti-human CD23 antibody according to Claim 3.
17. A pharmaceutical composition containing an
20 anti-human CD23 antibody according to Claim 4.

-129-

18. A pharmaceutical composition containing an anti-human CD23 antibody according to Claim 5.
19. A pharmaceutical composition containing an anti-human CD23 antibody according to Claim 6.
- 5 20. A pharmaceutical composition containing an anti-human CD23 antibody according to Claim 7.
21. A pharmaceutical composition containing an anti-human CD23 antibody according to Claim 8.
- 10 22. A pharmaceutical composition containing an anti-human CD23 antibody according to Claim 9.
23. A pharmaceutical composition containing an anti-human CD23 antibody according to Claim 10.
24. A pharmaceutical composition containing an anti-human CD23 antibody according to Claim 11.
- 15 25. The anti-human CD23 antibody of Claim 12, which is capable of inhibiting the binding of monoclonal anti-human CD23 antibody 5E8 to CD23.
26. A method of treating or preventing a disease condition wherein inhibition of IgE is therapeutically or
20 prophylactically beneficial comprising administering an effective amount of an antibody according to Claim 1.

-130-

27. A method of treating or preventing a disease condition wherein inhibition of IgE is therapeutically or prophylactically beneficial comprising administering an effective amount of an antibody according to Claim 2.

5 28. A method of treating or preventing a disease condition wherein inhibition of IgE is therapeutically or prophylactically beneficial comprising administering an effective amount of an antibody according to Claim 3.

10 29. A method of treating or preventing a disease condition wherein inhibition of IgE is therapeutically or prophylactically beneficial comprising administering an effective amount of an antibody according to Claim 4.

15 30. A method of treating or preventing a disease condition wherein inhibition of IgE is therapeutically or prophylactically beneficial comprising administering an effective amount of an antibody according to Claim 5.

20 31. A method of treating or preventing a disease condition wherein inhibition of IgE is therapeutically or prophylactically beneficial comprising administering an effective amount of an antibody according to Claim 6.

32. A method of treating or preventing a disease condition wherein inhibition of IgE is therapeutically or prophylactically beneficial comprising administering an effective amount of an antibody according to Claim 7.

-131-

33. A method of treating or preventing a disease condition wherein inhibition of IgE is therapeutically or prophylactically beneficial comprising administering an effective amount of an antibody according to Claim 8.

- 5 34. A method of treating or preventing a disease condition wherein inhibition of IgE is therapeutically or prophylactically beneficial comprising administering an effective amount of an antibody according to Claim 12.

- 10 35. The method of Claim 29, wherein the disease condition is an allergic disorder.

36. The method of Claim 29, wherein the disease condition is an autoimmune disease.

37. The method of Claim 29, wherein the disease condition is an inflammatory disease.

- 15 38. The anti-human CD23 monoclonal antibody of Claim 3, which is a human gamma-1 monoclonal antibody.

39. The anti-human CD23 monoclonal antibody of Claim 3, which is a human gamma-3 monoclonal antibody.

1/10

Effects of anti-human CD23 monoclonal antibodies on the production of IL4 induced IgE




FIGURE 1

2/10

Competition FACSscan Analysis of Anti-human CD23 Antibodies




FIGURE 2

3/10

Effects of primate 5E8 and PRIMATIZED® versions of 5E8 on
the production of IL4 induced IgE





FIGURE 3

Summary of *in vitro* Mab studies on primate monoclonal antibody 5E8 and
PRIMATIZED® versions of 5E8




Antibody	Apparent Kd (nM)	<i>In vitro</i> IgE suppression
primate 5E8	0.5, 1.5, 1.8, 4.4	+++
p5E8G4P	0.3, 1.0	+
p5E8G4PN-	0.3	+
p5E8G1	0.7	+++
p5E8G1N-	0.7	+++

FIGURE 4

5/10

FIGURE 5

Effects of primate 6G5 & PRIMATIZED® versions of 6G5
on the production of IL-4 induced IgE



6/10

Effects of primate anti-human CD23 monoclonal antibody 2C8
and 2C8 F(ab')₂ on IL-4 induced IgE production




FIGURE 6

7/10


2C8 F(ab')₂ antagonizes intact 2C8 suppression of IgE production

FIGURE 7

8/10





FIGURE 8



9/10

Comparison of primate 6G5 and PRIMATIZED® p6G5G4P on their effect on IgG and IgE production in hu-SCID mouse model (SCID24: 400 μ gx2)





FIGURE 9

10/10




FIGURE 10

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07K16/28 A61K39/395

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 92 17207 A (TANOX BIOSYSTEMS, INC.) 15 October 1992 see page 14, line 19 - page 15, line 20 ---	1-39
A	WO 93 02108 A (IDEC PHARMACEUTICALS CORPORATION) 4 February 1993 see claims see page 33, line 1 - line 5 ---	1-39
A	WO 87 07302 A (LABORATOIRES UNICET) 3 December 1987 see the whole document --- -/--	1-39

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

24 June 1998

Date of mailing of the international search report

15. 07. 1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Nooij, F

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	J-Y. BONNEFOY ET AL.: "Production and characterization of a monoclonal antibody specific for the human lymphocyte low affinity receptor for IgE: CD23 is a low affinity receptor for IgE." THE JOURNAL OF IMMUNOLOGY, vol. 138, no. 9, 1 May 1987, BALTIMORE, MD, USA, pages 2970-2978, XP002069160 see abstract ---	1-39
A	I. BOUGET ET AL.: "CD20 monoclonal antibodies decrease interleukin-4-stimulated expression of the low-affinity receptor for IgE (Fc epsilon RII/CD23) in human B cells by increasing the extent of its cleavage." EUROPEAN JURNAL OF IMMUNOLOGY, vol. 25, no. 7, July 1995, WEINHEIM, GERMANY, pages 1872-1876, XP002069161 see abstract -----	1-39

INTERNATIONAL SEARCH REPORT

Internal application No.
PCT/US 98/02253

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 26-37 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9217207 A	15-10-1992	EP 0585224 A	09-03-1994
WO 9302108 A	04-02-1993	AP 307 A	31-01-1994
		AU 673499 B	14-11-1996
		AU 2425592 A	23-02-1993
		BG 98411 A	28-02-1995
		BR 9206313 A	11-04-1995
		CA 2114015 A	04-02-1993
		CZ 9400149 A	13-07-1994
		EP 0605442 A	13-07-1994
		FI 940336 A	10-03-1994
		HU 70272 A	28-09-1995
		HU 211881 B	28-12-1995
		JP 6509708 T	02-11-1994
		MX 9204374 A	01-03-1993
		NO 940219 A	25-03-1994
		NZ 243706 A	26-08-1994
		OA 9879 A	15-09-1994
		PT 100735 A	29-10-1993
		SK 8894 A	07-09-1994
		US 5658570 A	19-08-1997
		US 5756096 A	26-05-1998
		US 5750105 A	12-05-1998
		US 5681722 A	28-10-1997
		US 5693780 A	02-12-1997
WO 8707302 A	03-12-1987	FR 2599513 A	04-12-1987
		DE 3775182 A	23-01-1992
		EP 0269728 A	08-06-1988
		JP 1500564 T	01-03-1989

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)